false FY 0001792941

 2023-03-31

 2024-01-15

 2023-01-01

 us-gaap: AccountingStandardsUpdate202006Member

 GNVR:PaycheckProtectionProgramMember

 2020-04-09

 GNVR:MelWentzMember

 GNVR:BarkleyCapitalLLCNoteMember

 2023-09-13

 GNVR:BarkleyCapitalLLCNoteMember

 2023-09-13
 2023-09-13

 GNVR:BrentLilienthalMember

 GNVR:BrentLilienthalMember

 GNVR:MelWentzMember

 GNVR:KirkHuntsmanMember

 GNVR:KirkHuntsmanMember

 GNVR:JohnHareMember

 GNVR:JohnHareMember

 GNVR:BarkleyCapitalLLCNoteMember

 GNVR:BarkleyCapitalLLCNoteMember

 2022-08-10

 2022-08-02
 2022-08-10

 GNVR:ChiefScientificOfficerAndChairmanMember

 GNVR:ChiefResearchOfficerAndDirectorMember

 GNVR:SettlementAgreementMember

 GNVR:SettlementAgreementMember

 2022-04-21
 2022-04-21

 2022-04-21

 2022-06-30

 GNVR:TransferAndExchangeAgreementMember

 2022-07-01
 2022-07-31

 GNVR:TransferAndExchangeAgreementMember

 2022-07-31

 GNVR:NexionContractorMember

 2022-09-08
 2022-09-08

 GNVR:BusinessAdvisoryServicesMember

 GNVR:BusinessAdvisoryServicesMember

 2022-02-18
 2022-02-18

 GNVR:DirectorOneMember

 GNVR:DirectorTwoMember

 GNVR:DirectorThreeMember

 srt: DirectorMember

 2022-04-01
 2022-04-30

 2022-09-13
 2022-09-13

 2021-10-01

 srt: MinimumMember

 srt: MaximumMember

 2022-02-28

 2022-02-28

 2022-05-12
 2022-05-12

 2022-05-12

 GNVR:SubscriptionAgreementsMember

 2022-07-01
 2022-07-31

 GNVR:DecemberTwentyTwentyOneStockPurchaseAgreementMember

 2022-07-01
 2022-07-31

 2022-11-17
 2022-11-17

 2023-05-03
 2023-05-03

 2023-05-12
 2023-05-12

 2023-05-29
 2023-05-29

 2023-07-12
 2023-07-12

 2023-07-13
 2023-07-13

 2023-07-14
 2023-07-14

 GNVR:InvestorOneMember

 2023-07-14
 2023-07-14

 2023-07-17
 2023-07-17

 GNVR:InvestorOneMember

 2023-07-17
 2023-07-17

 2023-08-25
 2023-08-25

 2023-09-16
 2023-09-16

 2023-09-19
 2023-09-19

 2023-06-14
 2023-06-14

 2023-07-01
 2023-07-01

 GNVR:JaynesInvestmentLLCMember

 GNVR:ACTHoldingsLLCMember

 GNVR:LASBFamilyTrustMember

 GNVR:JesseMichaelJaynesMember

 GNVR:BradleyWhiteMember

 GNVR:PJAdvisoryGroupMember

 2021-10-01

 GNVR:ConsultantMember

 2020-07-24
 2020-07-24

 GNVR:ConsultantMember

 2023-01-01

 GNVR:ConsultantMember

 2021-09-01
 2021-09-30

 us-gaap: ResearchAndDevelopmentArrangementMember

 us-gaap: ResearchAndDevelopmentArrangementMember

 GNVR:SettlementAgreementMember

 GNVR:SettlementAgreementMember

 GNVR:ExecutiveConsultingAgreementMember
 GNVR:MsMillerMember

 GNVR:ExecutiveConsultingAgreementMember
 GNVR:MsMillerMember

 GNVR:ChiefScientificOfficerAndChairmanMember

 GNVR:ChiefResearchOfficerAndDirectorMember

 GNVR:CEOAndBoardMember

 GNVR:CEOAndBoardMember

 2021-01-01

 GNVR:OldGenvorMember

 GNVR:OldGenvorMember

 GNVR:OldGenvorMember

 GNVR:OldGenvorMember

 2021-01-01

 GNVR:CommonStockOneMember

 GNVR:CommonStockTwoMember

 GNVR:CommonStockThreeMember

 GNVR:CommonStockFourMember

 GNVR:CommonStockOneMember

 GNVR:CommonStockTwoMember

 GNVR:CommonStockThreeMember

 GNVR:CommonStockFourMember

 2023-11-10
 2023-11-10

 2023-11-13
 2023-11-13

 2023-11-21
 2023-11-21

 2023-12-07
 2023-12-08

 2023-12-10
 2023-12-11

 2023-12-13
 2023-12-13

 2023-12-14
 2023-12-14

 2023-12-19
 2023-12-20

 2023-12-26
 2023-12-26

 2024-01-08
 2024-01-08

 U.S.
SECURITIES AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM

 Mark
One

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended: September 30, 2023

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from _________ to _________

 Commission
File No. 000-56589

 GENVOR
 INCORPORATED

 (Exact
 name of registrant as specified in its charter)

 Nevada

 83-2054746

 (State
 or Other Jurisdiction of

 Incorporation
 or Organization)

 (IRS
 Employer

 Identification
 Number)

S. Elliott Road, Suite 538

 Chapel
Hill, North Carolina 27514

 ( 984)
 261-7338

 (Address
and telephone number of principal executive offices)

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of each class

 Trading
 Symbol(s)

 Name
 of each exchange on which registered

 Not applicable

 Not applicable

 Not applicable

 Securities
registered under Section 12(g) of the Act:

 Common Stock, $0.001 par value

 (Title
of class)

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit and post such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based
compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to
§240.10D-1(b).

 On
March 31, 2023, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value
of the registrant's common stock held by non-affiliates of the registrant had an undetermined value as the registrant's common
stock was no t trading on any exchange, nor was it quoted for trading on the OTC Link ATS or any other over-the-counter market or alternative
trading system.

 The
number of the registrant's shares of common stock issued, issuable and outstanding was 19,623,536 as of January 15, 2024.

 TABLE
OF CONTENTS

 Page

 PART I.

 Item
 1.

 Business

 Item
 1A.

 Risk Factors

 Item
 1B.

 Unresolved Staff Comments

 Item
 2.

 Properties

 Item
 3.

 Legal Proceedings

 Item
 4.

 Mine Safety Disclosures

 PART II.

 Item
 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item
 6.

 Selected Financial Data

 Item
 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operation

 Item
 7A.

 Quantitative and Qualitative Disclosures About Market Risk

 Item
 8.

 Financial Statements and Supplementary Data

 Item
 9.

 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 Item
 9A.

 Controls and Procedures

 Item
 9B.

 Other Information

 PART III.

 Item
 10.

 Directors, Executive Officers and Corporate Governance

 Item
 11.

 Executive Compensation

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item
 14.

 Principal Accounting Fees and Services

 PART IV.

 Item
 15.

 Exhibits, Financial Statement Schedules

 Signatures

 Exhibits

 FORWARD
LOOKING STATEMENTS

 This
Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended,
and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements
are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and
our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes,"
"seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some
of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only
as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect
to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements for Genvor
Incorporated. Such discussion represents only the best present assessment from our Management.

 PART
I

 Item
1: Description of Business

Incorporated (the "Company" or "Genvor") was incorporated in Florida on September 26, 2018, as "Allure
Worldwide, Inc.," and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from "Allure
Worldwide, Inc." to "Genvor Incorporated."

 The
Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business
which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the "Purchase
Agreement") with Genvor Inc., a Delaware corporation ("Genvor") to acquire (the "Acquisition") Genvor.
On March 2, 2022, the Company and Genvor entered into a merger agreement (the "Merger Agreement") to consummate the Acquisition,
and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation ("Merger Subsidiary"),
would merge (the "Merger") with and into Genvor, with each share of Genvor common stock issued immediately prior to the time
of the merger automatically converted into the right to receive one share of common stock of the Company.

 On
May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right
to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor's pre-merger shareholders
(the "Merger Shares"), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the
Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the Acquisition,
and subsequently the Company's original founding shareholders cancelled 18,144,112 shares of Company common stock in connection
with the Acquisition.

 As
a result of the Acquisition, the Company's business plan is for Genvor to continue its research and development into sustainable
plant health solutions for future commercialization, leveraging its proprietary library of patented peptides, to provide crops with anti-pathogen
and enhanced nutritional properties to help farmers globally to overcome potentially catastrophic losses resulting from plant disease,
toxins, bacteria, and fungi that can destroy portions or all their crops. Genvor's peptide-based plant health solutions, when commercialized,
are expected to result in greater crop yields to assist in overcoming global food scarcity.

History

 The
Company's subsidiary, Genvor Inc., was incorporated under the laws of the State of Delaware on April 4, 2019, as "Nexion
Biosciences Inc.," and on January 22, 2020, its name was changed to "Genvor Inc." Genvor Inc. develops sustainable
plant health solutions, designed to provide crops with anti-pathogen and enhanced nutritional properties.

May 2019, Genvor Inc. acquired Nexion Biosciences LLC ("NBLLC") from its founder for nominal consideration. NBLLC was formed
in the State of Delaware on December 28, 2018.

technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who share a common mission to develop
crop protection technology to defend against deadly crop diseases, which ultimately impact both animals and humans alike. Genvor's
technology is currently being advanced by the USDA in corn seed varieties.

 Dr.
Jaynes has, over decades, focused on perfecting techniques for synthesizing and modifying anti-microbial peptides
("AMPs"). 1

headquarters are currently located at 201 S. Elliott Road, Suite 538, Chapel Hill, North Carolina, 27514.

Operations

 Overview

is a research and development ("R&D") company, advancing the next generation of sustainable plant health solutions, which
are designed to fight debilitating and deadly plant diseases, such as bacteria and fungi, in a broad spectrum of crop types through its
proprietary library of patented anti-microbial peptides, or AMPs. These AMPs can be applied to plants in the form of non-chemical seed
traits ("Transgenic" seed traits) – which imbue seeds with the desired traits, allowing plants to naturally produce
Genvor's AMPs – as well as a topical spray ("Bio-pesticide") application. The AMPs are intended to help farmers
worldwide achieve healthier and more productive crops, boosting yields and overcoming potentially catastrophic losses.

 With
critical global crop losses directly caused by plant disease exceeding $220 billion annually, 2 solutions utilizing peptide
technology are actively being evaluated worldwide. Genvor's proprietary library of patented peptides, utilizing only naturally
occurring substances, has been proven to enhance a plant's ability to defend itself. In addition to crop disease defense, Genvor
has created nutritional enhancement peptides ("NEPs") which increase protein output by 5-10x in poultry and swine feed, such
as corn or sweet potato, intended to deliver higher economic yields for farmers. Genvor's approach does not use any harsh chemicals,
which upon adoption should lead to reduced greenhouse gas emissions while conserving topsoil as compared to traditional petrochemical-based
solutions. These technologies should translate into substantial savings for potential customers, while concurrently providing a more
sustainable solution for organic or environmentally conscious growers.

 Below
is a summary of Genvor's peptide development process.

 1 See, e.g., Rajasekaran,
K. Jaynes, J.M. and Cary, J.W. (2009) Transgenic Expression of Lytic Peptides in Food and Feed Crops to Control Phytopathogens and pre-harvest
Mycotoxin Contamination. In: Mycotoxin Prevention and Control in Agriculture, Chapter 9, pp 119-142. American Chemical Society Symposium
Vol. 1031.

 Commercialization
of seed traits for corn, soy and cotton is among the Company's immediate goals, while simultaneously developing an effective topical
spray, and continued research into the nutritional enhancement of feed for swine and poultry. Genvor protects its comprehensive library
of 24 proprietary peptides with two issued United States patents, and a third patent pending covering an additional 16 peptides. The
following chart describes Genvor's peptide development pipeline, showing the relative stages of different peptides and crop application:

 Addressing
a $220 Billion Global Economic and Health Risk with Proven Solutions

 Food
production must double by 2050 to meet the food demand of the global population's expected growth to 9.6 billion people. Annual
crop losses due to plant pathogens and viruses are now estimated to exceed $220 billion globally. 3 Alarming to the United
States Food and Drug Administration ("FDA") is the fungi "Aspergillus Flavus," which produces Aflatoxins, a toxic
carcinogenic compound known to cause liver cancer in humans and animals. Humans infected with Aspergillus Flavus often have reduced or
compromised immune systems. Contamination of corn with acutely toxic and carcinogenic aflatoxin is a major human and livestock health
risk, estimated to cost the U.S. corn industry between $52 million and $1.7 billion annually. 4

 The below image shows an infected crop leaf, a common sight for farmers
facing these types of crop contamination issues:

 Aflatoxin
contamination causes market rejection of infected crops, as well as animal and human health impacts. The USDA has imposed strict guidelines
for crop inspection and discovery of diseased crops caused by Aflatoxins. Both planted fields and harvested crops found to be contaminated
exceeding permitted testing levels must be destroyed, at a loss to the farmer, who is often exposed to catastrophic economic losses as
a result. The guidelines in the European Union are stricter than in the United States, creating a critical market need for sustainable
and effective plant health solutions to combat such plant disease. 5

 Industry
observers have noted that seed trait expression of AMPs is a promising approach to providing resistance to aflatoxin infection in corn. 6
 Testing of Genvor's AMPs by the US Department of Agriculture over a period of six years, the results of which were published
in May 2018 and March 2023, showed promising results in defense against aflatoxins, as seeds infused with Genvor AMPs showed a 70% reduction
in aflatoxin contamination, making them promising candidates for genetic engineering the next-generation of disease-resistant crops. 7

 Application
of Peptides in Plant Protection

 Plant
pathogens attack crops and lead to serious adverse impacts on their growth. Traditional chemical fungicides are effective in preventing
diseases caused by plant pathogens; however, their long-term continuous use has led to plant pathogens developing resistance to those
fungicides, and their residues present a risk of harm to humans and the environment. Industry observers believe that more sustainable
methods to control plant diseases are urgently needed. 8 Naturally occurring AMPs mediate the innate host defense and can be
used as immune inducers. Given their high specificity, rapid degradation, and efficacy, AMPs are expected to be a promising
first line of defense against fungi, viruses, and bacteria. Some industry observers believe that peptides will likely become mainstream
tools for plant protection in the future. 9

 Id.

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes

 Id.

 Science Direct - Advanced Agrochem: Volume 2, Issue 1, March 2023, Pages 58-78, Peptides, new tools for plant protection in
eco-agriculture. Yi-Meng Zhang, De-Xing Ye, Yan Liu, Xin-Yuan Zhang, Yuan-Lin Zhou, Li Zhang, Xin-Ling Yang.

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes

 Donley N. The USA lags behind other agricultural nations in banning harmful pesticides. Environ Health Glob Access Sci Source.
2019;18(1):44.

 Science Direct - Advanced Agrochem: V olume 2, Issue 1, March 2023, Pages 58-78, Peptides, new tools for plant
protection in eco-agriculture. Yi-Meng Zhang, De-Xing Ye, Yan Liu, Xin-Yuan Zhang, Yuan-Lin Zhou, Li Zhang, Xin-Ling Yang.

 The following is an illustration that shows the mode of action of Genvor's
peptides against a disease cell:

AMP Technology has Created Significant Economic Opportunities in a Broad Spectrum of Plant Types

 The
Aflatoxin problem has created significant opportunities for companies developing the technology needed to defend against Aflatoxins.
AMPs, such as those developed by Genvor, are a safer alternative to fungicides. Pesticides or fungicides with a chemical composition
are known to degrade the environment, are inefficient to apply, persist in crops and livestock, and are less effective as plant pathogen
resistance increases. AMPs kill microorganisms directly, resistance to them is rare and should remain so given their mode of action,
and AMPs can be manufactured via a non-GMO process.

peptides have proven effective on corn and show broad spectrum effectiveness for other crop types 11 for most known bacteria
and fungi within a single product solution. This broad-spectrum efficacy should be more efficient for farmers compared to the toxic fungicide
alternatives, which are currently used to combat a single fungi or bacteria type. Genvor's technology can be delivered into plants
by both bioengineered seed traits, as well as through bio-fungicide (topical spray) application. 11 There is no evidence of
pathogens developing resistance to Genvor's designed AMPs. At this point in time, AMPs show a likelihood of killing pathogens
in berries, corn, cannabis, wheat, cotton, citrus, and peanuts.

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca
 R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes and Kanniah Rajasekaran, March 20, 2023.

 Id.

 What
are Peptides Exactly?

 Peptides
are broadly utilized in medicine, cosmetics, healthcare products, animal nutrition and health, and plant nutrition and protection. In
recent years, they've become active research subjects to protect plants from bacteria, viruses, pests, and weeds, as antimicrobial
and immune inducers, plant growth regulators, insecticides, and herbicides. This is due to their extensive raw material sources, excellent
activity, and ideal environmental compatibility.

 Peptides
are short-chain biomolecules of between 2 and 50 amino acids, linked by peptide bonds. Based on their sources, peptides can be categorized
as natural or artificially synthesized. Most natural peptides are from animals, plants, and microorganisms. Both natural and synthetic
peptides can be produced through chemical synthesis, biological fermentation, gene recombination and other methods. Peptides are ubiquitous
in living organisms and modulate many physiological processes, making them a common research subject in medicine, cosmetics, and agriculture. 12

 How
do Peptides Work Against Diseases?

 Through
seed traits, plant seeds are genetically coded to produce AMPs. Upon encountering a disease microbe, AMPs penetrate the cell wall of
the target disease microbe, causing the contents of the disease microbe to spill out, destroying the disease cell. The same effect is
foreseen in the utilization of the topical spray.

 Delivery
by Transgenic Seed Traits

 In
North America, the seed trait market is currently estimated to exceed $10 billion. The adoption of crop seeds with enhanced traits has
been staggering with over 75% of U.S. corn, cotton and soybeans being produced using seeds with enhanced traits. 13

 The following image shows corn with Genvor's seed traits, which is
currently growing in a USDA facility for study:

 Science Direct - Advanced Agrochem: Volume 2, Issue 1, March 2023, Pages 58-78, Peptides, new tools for plant
protection in eco-agriculture. Yi-Meng Zhang, De-Xing Ye, Yan Liu, Xin-Yuan Zhang, Yuan-Lin Zhou, Li Zhang, Xin-Ling Yang.

 Delivery
by Topical Spray (Bio-fungicide)

 The
rising global demand for organic foods, the trend in the reduction of chemical residues, stricter import and supermarket standards, shorter
pre-harvest intervals, a push for sustainability, growing food scarcity, the phase out of synthetic agricultural chemicals, along with
the market's demand for additional modes of action to manage resistance, has resulted in biologicals being one of the fastest-growing
sectors in the crop protection market, increasing at twice the compound annual growth rate of the crop protection market as a whole. 14
 The global agricultural biologicals market was approximately $9.5 billion in 2019 and is expected to grow to approximately $19.7
billion by 2026. 15 Unlike synthetic chemicals, bio-fungicides are derived from configurations of amino acids and proteins
occurring in nature; therefore they do not contaminate soil, water, turf, beneficial insects, birds, fish, and non-targeted plants. 16

 USDA
Partnership – Benefits of a CRADA

AMPs gained the attention of the USDA in its pursuit of solutions for plant disease in corn, the U.S.'s largest crop. Based on
over 30 years of research by Genvor founder Dr. Jesse Jaynes, Genvor was awarded a Cooperative Research and Development Agreement ("CRADA")
in 2018 to develop and commercialize disease resistance and nutritional enhancement in corn seed based upon Genvor's proven technology.
A CRADA expands expertise and speeds development of many technologies that are now used by farmers or found in the grocery store through
access to USDA resources such as advanced laboratories, increasing the chances that research outcomes are adopted commercially to maximize
impact, driving a significantly lower overhead rate than a university's research program, and creating a multi-disciplinary research
team to increase technical breadth and depth of the lab. In addition, a CRADA provides access to the USDA regulatory team for registrations
and processes.

Peptides are proven effective in corn seed traits.

 As
a result of the USDA and Genvor partnership through the CRADA, the effectiveness of Genvor's solutions in protecting against Aflatoxins
in corn seed has been established, with the probability that this technology can effectively be applied to other crop types. 17 Genvor
is expecting an extension of the CRADA to continue the studies of Genvor's 4 th generation of its peptides (GNV-185 and
GNV-187) towards commercialization. The Company now has the technology to move its superior AMPs from the research lab and greenhouse
to the field, with the goal of commercially producing Genvor's AMPs at a desirable price point for cost-effective and broad-based
agricultural use.

 What
is a USDA CRADA Worth to Genvor?

 In
the United States, it often takes eight years and $136 million to develop and bring a new seed trait through regulatory to the marketplace. 18
 The value of a CRADA, utilizing the USDA's existing labs, know-how, research, fields, greenhouses, and oversight to develop
a Seed Trait for corn is significant as it allows Genvor to bring seed traits to market with substantially less capital investment. For
its CRADA in corn, Genvor's contribution was under $700,000, primarily for a dedicated scientist to work onsite at the USDA facility
over the years. Genvor is expecting to continue R&D of its anti-microbial and nutritional enhancement peptides ("NEPs")
for poultry and swine feed through additional CRADAs with the USDA. In addition, Genvor is planning to apply for a CRADA for Aflatoxins
in peanuts. The USDA partnership is based upon the confidence and proof of concept found in Genvor's solutions.

 Below
is a chart showing the average surveyed development costs of bring a new plant trait to market in the United States:

 Business
Strategy: Licensing First and Leveraging R&D with Third Parties

business model is to remain capital-light, focused on leveraging its third-party research and development through its initial CRADA with
the USDA, and any subsequent CRADAs that may be granted, while also adopting a licensing approach to reduce "cash burn" or
the need for significant manufacturing and marketing overhead. Genvor is highly scalable and capital efficient with minimal overhead
relative to peers, allowing the Company to focus on core research and development competency. Genvor does not expect revenue until the
end of 2025, through the licensing and distribution of either or both the topical spray and seed trait, utilizing licensing and royalty
opportunities.

 15 Id.

 16 Id.

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes

 18

 Citrus
Licensing with Royalty

has established an initial licensing and royalty agreement with Southern Gardens Citrus, a division of U.S. Sugar, operating 6,600 acres
of orange groves in Florida, utilizing Genvor's AGM-176 and AGM-179 peptides, proving the effectiveness of these peptides on the
crippling problems of canker on citrus crops. While 5+ years of studies showed the effectiveness of Genvor's AGM-176 and AGM-179,
Southern Gardens has not yet taken the usage of these solutions through regulatory approval for commercialization, which should generate
royalty revenue to Genvor following receipt of such approval.

 Discussions
with Additional Third-Party Crop Growers

is in discussions with other major growers of other crop types regarding the potential funding of Genvor's costs of research and
development through to seed traits, topical spray, or both – all as a solution to fight toxins, bacteria or fungi that damage various
spectrums of crop types. A licensing and royalty agreement with those growers are likely outcomes of any R&D funding agreement.

 Financing
Needs

is currently exploring financing options to generate the cash needed to pay for overhead, marketing, and production of peptides
to be used in R&D, contributions to the CRADA and regulatory costs to take existing technology through the process. Additional
financing may be required in the event self-funded R&D is needed. There are no plans currently to create Genvor's own labs,
greenhouses or fields or its research with the availability of utilizing existing labs, scientific and regulatory professionals –
chiefly through its CRADA with the USDA.

 Competition

 Below
are some of Genvor's agriscience competitors.

 Invaio
Sciences - Peptide maSAMP ( is used to control citrus Huanglongbing, a destructive disease.

 Plant
Health Care - PREtec technology ( from the American Plant Health Care (PHC) company, was patented
in the United States in 2019. Its unique immune-inducing peptides and its mixtures with other products have been recognized for strengthening
plant resistance to disease and stress, as well as promoting plant growth. All PREtec peptides are variants of natural proteins and break
down rapidly in the environment, leaving no harmful residues on the crop or in the environment. In 2021, PHC launched PHC279 with PREtec
technology in Brazil and sold it under the name of Saori. This product is used as a seed treatment to prevent Asian soybean rust.

 PHYTOTECH
LABS FLG22 ( from Phytotech, induces the natural immune response. Its sequence was derived from the highly
conserved N-terminal region of Pseudomonas aeruginosa flagellin. FLG22 and its derivatives induce defense responses in Lycopersicon esculentum
and Arabidopsis thaliana and have elicitor activity. Many immune induction peptides are in development.

 CEV,
SA (CEV) ( established in 2006 with the objective of developing a new patented protein-based bio-fungicide. The
active ingredient is a polypeptide, named BLAD, which is extracted from the germinated seeds of lupines. BLAD's multi-site targets
cell walls, cell membrane and cell metabolism.

 Syngenta
Global  Syngenta is a world market leader in crop protection products, developing and producing herbicides,
insecticides, fungicides and seed treatment products for farmers and growers.

 Hello
Nature -  / offers a range of biotechnological and certified solutions for modern and sustainable
agriculture including natural bio-stimulants of vegetal origin, beneficial microbials and organic fertilizers.

 Sym
Agro -  serves horticultural and agricultural specialty markets with an assortment of fertilizers, fungicides,
biologics, and pesticides. ProBlad Verde fungicide is available in the US for use on a variety of crops, including stone fruit,
cane berries, strawberries, pome fruits, grapes, almonds, leafy greens, herbs, and tomatoes.

 Innatrix
– Products under development in their pipeline: InnaLB (Potato Late Blight) - Peptide product to stop late blight infection,
by interfering with critical late blight effectors, InnaNema (Soybean Cyst Nematode) Seed treatment product to stop nematode infection
and reproduction process on soybean roots, by RNAi technology, and nnaHLB (Citrus Greening) Peptide product to stop citrus greening
infection by interfering with critical citrus greening effector.

History

 The
Company's subsidiary, Genvor Inc. was incorporated under the laws of the State of Delaware on April 4, 2019, as "Nexion Biosciences
Inc.," and on January 22, 2020, its name was changed to "Genvor Inc." Genvor Inc. develops plant-based defense technology,
which improves upon a plant's natural defenses. Genvor's mission is to help farmers and growers world-wide to increase their
yield to potentially overcome catastrophic losses resulting from plant disease, toxins, bacteria, and fungi that destroy their crops.

May 2019, Genvor Inc. acquired Nexion Biosciences LLC ("NBLLC") from a founder for nominal consideration. NBLLC was formed
in the State of Delaware on December 28, 2018.

technology was developed by two university scientists, Dr. Clayton Yates, and Dr. Jesse Jaynes, who shared a mission to develop crop
protection technology designed to defend against deadly crop diseases affecting both animals and humans alike. Genvor's technology
is currently being advanced by the USDA in corn seed varieties and Southern Gardens, a subsidiary of U.S. Sugar, in citrus trees.

 Dr.
Jaynes and Dr. Yates have, over decades, focused on perfecting techniques for synthesizing and modifying antimicrobial peptides (AMPs). 19

headquarters is located at 201 S. Elliott Road, Suite 538, Chapel Hill, North Carolina 27514.

 Reports
to Security Holders

 We
intend to furnish our shareholders annual reports containing financial statements audited by our independent registered public accounting
firm and to make available quarterly reports containing unaudited financial statements for each of the first three quarters of each year.
We file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange
Commission voluntarily to disclose material information regarding the Company to the public. We may also file additional documents
with the Commission if they become necessary in the course of our company's operations.

 The
public may read and copy any materials that we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington,
D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The
SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC. The address of that site is www.sec.gov.

 Government
Regulations

 We
believe that we are and will continue to be in compliance in all material respects with applicable statutes and the regulations passed
in the United States. There are no current orders or directions relating to our company with respect to the foregoing laws and regulations.

 19 See, e.g., Rajasekaran, K. Jaynes,
J.M. and Cary, J.W. (2009) Transgenic Expression of Lytic Peptides in Food and Feed Crops to Control Phytopathogens and pre-harvest Mycotoxin
Contamination. In: Mycotoxin Prevention and Control in Agriculture, Chapter 9, pp 119-142. American Chemical Society Symposium Vol. 1031.

 Environmental
Regulations

 While
our products and business activities do not currently violate any laws, any regulatory changes that impose additional restrictions or
requirements on us or on our products or potential customers could adversely affect us by increasing our operating costs or decreasing
demand for our products or services, which could have a material adverse effect on our results of operations.

 Employees

 As
of September 30, 2023, we had no full-time employees.

 Property

 The
Company does not own or rent property. The Company's office space is provided by an officer at no charge.

 Item
1A. Risk Factors

 As
a smaller reporting company, we are not required to provide the information required by this item.

 Item
1B. Unresolved Staff Comments.

 None.

 Item
2. Properties

 We
do not own any real estate or other properties.

 Item
3. Legal Proceedings

 Management
is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. Except as set forth below, as
of the date of this Annual Report, no director, officer, or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has
an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been
threatened against us or our properties.

 On September 28, 2023, the Company entered into a Settlement Agreement
with Bradley White, the Company's former CEO and director of the Company, who was terminated on June 20, 2023, to settle threatened
claims by each of White and the Company against the other. Pursuant to the Settlement Agreement, (i) the Company and Mr. White waived
claims against the other, (ii) Mr. White was to receive settlement payments of $300,000, payable in tranches of $50,000, beginning on
September 28, 2023, or within seven days, and each subsequent payment on the monthly anniversary of the Settlement Agreement execution,
and (iii) Mr. White agreed to return to the Company for cancellation shares of stock controlled by him, including 3 shares of Series A
Preferred Stock and 502,512 shares of Series B Preferred Stock. Mr. White has returned those shares of preferred stock to the Company
for cancellation, and $150,000 in payments have been made to Mr. White as of the date hereof.

 Item
4. Mine Safety Disclosures

 Not
applicable to our Company.

 PART
II

 Item
5. Market for Common Equity and Related Stockholder Matters

 Market
Information

 There is no "established trading market"
for shares of the Company's common stock. As of the date hereof, the Company's common stock was quoted on the OTC Link LLC alternative
trading system operated by OTC Markets Group, Inc. under the symbol "GNVR." No assurance can be given that any "established
trading market" for the Company's common stock will develop or be maintained.

 Our stock was first quoted on the
OTC Link LLC beginning in the fourth fiscal quarter for the year ended September 30, 2023, but did not commence trading until
approximately December 1, 2023. The range of high and low closing bid quotations for the Company's common stock during each
quarter of the calendar years ended September 30, 2023, and 2022, is shown below, as quoted by www.otcmarkets.com. Prices
are inter-dealer quotations, without retail mark-up, markdown or commissions and may not represent actual transactions.

 Stock Quotations

 Quarter Ended

 High

 Low

 December 31, 2021

 -

 -

 March 31, 2022

 -

 -

 June 30, 2022

 -

 -

 September 30, 2022

 -

 -

 December 31, 2022

 -

 -

 March 31, 2023

 -

 -

 June 30, 2023

 -

 -

 September 30, 2023

 4.00

 4.00

 The future sale of the Company's presently outstanding
"unregistered" and "restricted" common stock by present members of management and persons who own more than five percent
of the Company's outstanding voting securities may have an adverse effect on any "established trading market" that may develop
in the shares of the Company's common stock.

 Holders

 As of November 7, 2023, the Company had approximately
167 shareholders of record of common stock, including shares held in "street name" by banks, brokerage clearing houses, depositories
or otherwise in unregistered form.

 Transfer Agent

 The
Company's transfer agent is Securities Transfer Corporation, Securities Transfer Corporation, 2901 N. Dallas Parkway, Suite 380,
Plano, Texas, 75093, Telephone: (469) 633-0088.

 Dividend
Distributions

 We
have not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our future
dividend policy will be determined from time to time by our board of directors.

 Securities
authorized for issuance under equity compensation plans.

 The
Company does not have a stock option plan.

 Penny
Stock

 Our
common stock is considered "penny stock" under the rules of the Securities and Exchange Commission (the
"SEC") under the Securities Exchange Act of 1934. The SEC has adopted rules that regulate broker-dealer practices in
connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other
than securities registered on certain national securities exchanges or quoted on the NASDAQ Stock Market System, provided that
current price and volume information with respect to transactions in such securities is provided by the exchange or quotation
system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk
disclosure document prepared by the Commission, that:

 contains
 a description of the nature and level of risks in the market for penny stocks in both public offerings and secondary trading;

 contains
 a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer
 with respect to a violation to such duties or other requirements of Securities' laws; contains a brief, clear, narrative description
 of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

 contains
 a toll-free telephone number for inquiries on disciplinary actions;

 defines
 significant terms in the disclosure document or in the conduct of trading in penny stocks; and

 contains
 such other information and is in such form, including language, type, size and format, as the Commission shall require by rule or
 regulation.

 The
broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with:

 bid
 and offer quotations for the penny stock;

 the
 compensation of the broker-dealer and its salesperson in the transaction;

 the
 number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the
 marker for such stock; and

 monthly
 account statements showing the market value of each penny stock held in the customer's account.

 In
addition, the penny stock rules that require that prior to a transaction in a penny stock not otherwise exempt from those rules; the
broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the
purchaser's written acknowledgement of the receipt of a risk disclosure statement, a written agreement to transactions involving
penny stocks, and a signed and dated copy of a written suitably statement.

 These
disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.

 Related
Stockholder Matters

 Unregistered
Sales of Equity Securities

 On
July 1, 2023, the Company issued 29,665 shares of common stock related to the conversion of a note payable and accrued interest for $14,833.

 On
July 12, 2023, the Company issued 20,000 shares of common stock to an investor for $10,000.

 On
July 13, 2023, the Company issued 20,000 shares of common stock to an investor for $10,000.

 On
July 14, 2023, the Company issued 50,000 shares of common stock to an investor for $25,000.

 On
July 17, 2023, the Company issued 25,000 shares of common stock to an investor for $10,000.

 On July 17, 2023, the Company issued 50,000 shares of common stock to an
investor for $25,000.

 On
August 25, 2023, the Company issued 50,000 shares of common stock to an investor for $25,000.

 On
September 16, 2023, the Company issued 75,000 shares of common stock to an investor for $25,000.

 On
September 19, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

the year ended September 30, 2023, the Company issued 2,362,900 warrants for common stock of the Company. The issuances were for the
following:

 by a third-party consultant – On September 29, 2023, 162,900 warrants for common stock with an exercise price of $0.001,
 valued at $142,900

 by related party, Judith S. Miller, the Company's Interim CEO and CFO – On September 29, 2023, 600,000 warrants for common with an exercise price of $0.001, valued at $600,000

 Settlement
 of debt with a third party – On September 29, 2023, 200,000 warrants for common stock with an exercise price of $0.001, valued
 at $200,000

 Conversion
 of notes payable and accrued interest to a third party – On September 29, 2023, 1,400,000 warrants for common stock with an
 exercise price of $0.001, valued at $359,414

 On
November 1, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

 On
November 1, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.

 On
November 1, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

 On
November 1, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

 On
November 8, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

 On
November 8, 2023, the Company issued 25,000 shares of common stock to an investor for $25,000.

 On
November 8, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

 On
November 8, 2023, the Company issued 20,000 shares of common stock to an investor for $20,000.

 On
November 10, 2023, the Company issued 25,600 shares of common stock to an investor for $25,600.

 On
November 13, 2023, the Company issued 20,000 shares of common stock for $20,000.

 On
November 21, 2023, the Company issued 250,000 warrants for common stock to Good Works Funding (which is controlled by our Interim CEO
and CFO, Judith S. Miller) for a milestone on their consulting agreement.

 On
December 8, 2023, the Company issued 50,000 shares of common stock to an investor for $50,000.

 On December 11, 2023, the Company issued 10,000 shares
of common stock to an investor for $10,000.

 On December 13, 2023, the Company issued 100,000 shares of common stock for $100,000.

 On December 14, 2023, the Company issued 50,000 shares
of common stock to an investor for $50,000.

 On December 20, 2023, the Company issued 53,000 shares of common stock
tfo an investor for $53,000.

 On
December 26, 2023, the Company issued 50,000 shares of common stock for $50,000.

 On January 8, 2024, the Company issued 8,000 shares of common stock for $8,000.

 The
forgoing securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933,
as amended, and Rule 506(b) promulgated thereunder, as there was no general solicitation, and the transactions did not involve a public
offering.

 Purchase
of Equity Securities

 None.

 Item
6. Selected Financial Data

 As
the Company is a "smaller reporting company," this item is inapplicable.

 Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 This
Annual Report on Form 10-K contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended,
and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements
are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs, and
our assumptions. Words such as "anticipate," "expects," "intends," "plans," "believes,"
"seeks" and "estimates" and variations of these words and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some
of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only
as of the date of this Form 10-K. Investors should carefully consider all of such risks before making an investment decision with respect
to the Company's stock. The following discussion and analysis should be read in conjunction with our financial statements and summary
of selected financial data for the Company. Such discussion represents only the best present assessment from our Management.

 DESCRIPTION
OF COMPANY

Incorporated (the "Company") was incorporated in Florida on September 26, 2018, as Allure Worldwide, Inc., and as of November
18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from Allure Worldwide, Inc. to Genvor Incorporated.

 The
Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business
which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the "Purchase
Agreement") with Genvor Inc., a Delaware corporation ("Genvor") to acquire (the "Acquisition") Genvor.
On March 2, 2022, the Company and Genvor entered into a merger agreement (the "Merger Agreement") to consummate the Acquisition,
and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the "Merger")
with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted
into the right to receive one share of common stock of the Company.

 On
May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right
to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor's pre-merger shareholders
(the "Merger Shares"), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the
Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share
exchange with Genvor, and subsequently the Company's original founding shareholders cancelled 18,144,112 shares of Company common
stock in connection with the Acquisition.

 As
a result of the Acquisition, the Company's business plan is that Genvor will be continuing its research and development addressing
plant-based defense technology ich then can be commercialized to help farmers and growers globally to overcome potentially catastrophic
losses resulting from plant disease, toxins, bacteria, and fungi that destroy their crops. These solutions can result in greater crop
yields and economic savings, which can assist in overcoming world-wide food scarcity.

 The
Company's technology was developed by two university scientists, Dr. Clayton Yates, and Dr. Jesse Jaynes, who shared a mission
to develop crop protection technology designed to defend against crop diseases affecting both animals and humans alike. The
Company's technology is currently being advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus
trees.

 The
Company's headquarters is located at 201 S. Elliott Road, Suite 538, Chapel Hill, NC. 27514.

 The
following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included
in this Form 10-Q.

 Plan
of Operation

Incorporated (the "Company" or "Genvor") was incorporated in Florida on September 26, 2018, as "Allure
Worldwide, Inc.," and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from "Allure
Worldwide, Inc." to "Genvor Incorporated."

 The
Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business
which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the "Purchase
Agreement") with Genvor Inc., a Delaware corporation ("Genvor") to acquire (the "Acquisition") Genvor.
On March 2, 2022, the Company and Genvor entered into a merger agreement (the "Merger Agreement") to consummate the Acquisition,
and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the "Merger")
with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted
into the right to receive one share of common stock of the Company.

 On
May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right
to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor's pre-merger shareholders
(the "Merger Shares"), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the
Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share
exchange with Genvor, and subsequently the Company's original founding shareholders cancelled 18,144,112 shares of Company common
stock in connection with the Acquisition.

 As
a result of the Acquisition, the Company's business plan is that of Genvor, and the Company is developing plant-based defense technology
designed to help farmers achieve global food security.

History

 The
Company's subsidiary, Genvor Inc. was incorporated under the laws of the State of Delaware on April 4, 2019, as "Nexion Biosciences
Inc.," and on January 22, 2020, its name was changed to "Genvor Inc." Genvor Inc. develops plant-based defense technology
designed to help farmers achieve global food security.

May 2019, Genvor Inc. acquired Nexion Biosciences LLC ("NBLLC") from a founder for nominal consideration. NBLLC was formed
in the State of Delaware on December 28, 2018.

technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection
technology designed to defend against crop diseases effecting both animals and humans alike. Genvor's technology is currently being
advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

headquarters is located at 201 S. Elliott Road, Suite 538, Chapel Hill, North Carolina 27514.

Operations

 Overview

 Genvor's technology was
developed by two university scientists, Dr. Clayton Yates, and Dr. Jesse Jaynes, who share a common mission to develop crop
protection technology to defend against deadly crop diseases, which ultimately impact both animals and humans alike. Genvor's
technology is currently being advanced by the USDA in corn seed varieties.

 Dr. Jaynes has, over decades, perfected techniques for synthesizing and
modifying anti-microbial peptides ("AMPs"). 1

is a research and development ("R&D") company, advancing the next generation of sustainable plant health solutions, which
are designed to fight debilitating and deadly plant diseases, such as bacteria and fungi, in a broad spectrum of crop types through its
proprietary library of patented anti-microbial peptides, or AMPs. These AMPs can be applied to plants in the form of non-chemical seed
traits ("Transgenic" seed traits) – which imbue seeds with the desired traits, allowing plants to naturally produce
Genvor's AMPs – as well as a topical spray ("Bio-pesticide") application. The AMPs are intended to help farmers
worldwide achieve healthier and more productive crops, boosting yields and overcoming potentially catastrophic losses.

 1 See,
e.g., Rajasekaran, K. Jaynes, J.M. and Cary, J.W. (2009) Transgenic Expression of Lytic Peptides in Food and Feed Crops to Control
Phytopathogens and pre-harvest Mycotoxin Contamination. In: Mycotoxin Prevention and Control in Agriculture, Chapter 9, pp 119-142.
American Chemical Society Symposium Vol. 1031.

 With
critical global crop losses directly caused by plant disease exceeding $220 billion annually, 2 solutions utilizing peptide
technology are actively being evaluated worldwide. Genvor's proprietary library of patented peptides, utilizing only naturally
occurring substances, has been proven to enhance a plant's ability to defend itself. In addition to crop disease defense, Genvor
has created nutritional enhancement peptides ("NEPs") which increase protein output by 5-10x in poultry and swine feed, such
as corn or sweet potato, intended to deliver higher economic yields for farmers. Genvor's approach does not use any harsh chemicals,
which upon adoption should lead to reduced greenhouse gas emissions while conserving topsoil as compared to traditional petrochemical-based
solutions. These technologies should translate into substantial savings for potential customers, while concurrently providing a more
sustainable solution for organic or environmentally conscious growers.

 Below
is a summary of Genvor's peptide development process.

 Commercialization
of seed traits for corn, soy and cotton is among the Company's immediate goals, while simultaneously developing an effective topical
spray, and continued research into the nutritional enhancement of feed for swine and poultry. Genvor protects its comprehensive library
of 24 proprietary peptides with two issued United States patents, and a third patent pending covering an additional 16 peptides. The
following chart describes Genvor's peptide development pipeline, showing the relative stages of different peptides and crop applications:

 Addressing
a $220 Billion Global Economic and Health Risk with Proven Solutions

 Food
production must double by 2050 to meet the food demand of the global population's expected growth to 9.6 billion people. Annual
crop losses due to plant pathogens and viruses are now estimated to exceed $220 billion globally. 3 Alarming to the United
States Food and Drug Administration ("FDA") is the fungi "Aspergillus Flavus," which produces Aflatoxins, a toxic
carcinogenic compound known to cause liver cancer in humans and animals. Humans infected with Aspergillus Flavus often have reduced or
compromised immune systems. Contamination of corn with acutely toxic and carcinogenic aflatoxin is a major human and livestock health
risk, estimated to cost the U.S. corn industry between $52 million and $1.7 billion annually. 4

 The below image shows an infected crop leaf, a common sight for farmers
facing these types of crop contamination issues:

 Id.

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes

 Aflatoxin
contamination causes market rejection of infected crops, as well as animal and human health impacts. The USDA has imposed strict guidelines
for crop inspection and discovery of diseased crops caused by Aflatoxins. Both planted fields and harvested crops found to be contaminated
exceeding permitted testing levels must be destroyed, at a loss to the farmer, who is often exposed to catastrophic economic losses as
a result. The guidelines in the European Union are stricter than in the United States, creating a critical market need for sustainable
and effective plant health solutions to combat such plant disease. 5

 Industry
observers have noted that seed trait expression of AMPs is a promising approach to providing resistance to aflatoxin infection in corn. 6
 Testing of Genvor's AMPs by the US Department of Agriculture over a period of six years, the results of which were published
in May 2018 and March 2023, showed promising results in defense against aflatoxins, as seeds infused with Genvor AMPs showed a 70% reduction
in aflatoxin contamination, making them promising candidates for genetic engineering the next-generation of disease-resistant crops. 7

 Application
of Peptides in Plant Protection

 Plant
pathogens attack crops and lead to serious adverse impacts on their growth. Traditional chemical fungicides are effective in preventing
diseases caused by plant pathogens; however, their long-term continuous use has led to plant pathogens developing resistance to those
fungicides, and their residues present a risk of harm to humans and the environment. Industry observers believe that more sustainable
methods to control plant diseases are urgently needed. 8 Naturally occurring AMPs mediate the innate host defense and can
be used as immune inducers. Given their high specificity, rapid degradation, and efficacy, AMPs are expected to be a promising
first line of defense against fungi, viruses, and bacteria. Some industry observers believe that peptides will likely become mainstream
tools for plant protection in the future. 9

 Id.

 Science Direct – Advanced Agrochem: Volume 2, Issue 1, March 2023, Pages 58-78, Peptides, new tools for plant protection in
eco-agriculture. Yi-Meng Zhang, De-Xing Ye, Yan Liu, Xin-Yuan Zhang, Yuan-Lin Zhou, Li Zhang, Xin-Ling Yang.

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes

 Donley N. The USA lags behind other agricultural nations in banning harmful pesticides. Environ Health Glob Access Sci Source.
2019;18(1):44.

 9 Science
Direct – Advanced Agrochem: Volume 2, Issue 1, March 2023, Pages 58-78, Peptides, new tools for plant protection in
eco-agriculture. Yi-Meng Zhang, De-Xing Ye, Yan Liu, Xin-Yuan Zhang, Yuan-Lin Zhou, Li Zhang, Xin-Ling Yang.

 The following is an illustration that shows the mode of action of Genvor's
peptides against a disease cell:

AMP Technology has Created Significant Economic Opportunities in a Broad Spectrum of Plant Types

 The
Aflatoxin problem has created significant opportunities for companies developing the technology needed to defend against Aflatoxins.
AMPs, such as those developed by Genvor, are a safer alternative to fungicides. Pesticides or fungicides with a chemical composition
are known to degrade the environment, are inefficient to apply, persist in crops and livestock, and are less effective as plant pathogen
resistance increases. AMPs kill microorganisms directly, resistance to them is rare and should remain so given their mode of action,
and AMPs can be manufactured via a non-GMO process.

peptides have proven effective on corn and show broad spectrum effectiveness for other crop types 10 for most known bacteria
and fungi within a single product solution. This broad-spectrum efficacy should be more efficient for farmers compared to the toxic fungicide
alternatives, which are currently used to combat a single fungi or bacteria type. Genvor's technology can be delivered into plants
by both bioengineered seed traits, as well as through bio-fungicide (topical spray) application. 11 There is no evidence of
pathogens developing resistance to a Genvor's designed AMPs. At this point in time, AMPs show a likelihood of killing pathogens
in berries, corn, cannabis, wheat, cotton, citrus, and peanuts.

 What
are Peptides Exactly?

 Peptides
are broadly utilized in medicine, cosmetics, healthcare products, animal nutrition and health, and plant nutrition and protection. In
recent years, they've become active research subjects to protect plants from bacteria, viruses, pests, and weeds, as antimicrobial
and immune inducers, plant growth regulators, insecticides, and herbicides. This is due to their extensive raw material sources, excellent
activity, and ideal environmental compatibility.

 Peptides
are short-chain biomolecules of between 2 and 50 amino acids, linked by peptide bonds. Based on their sources, peptides can be categorized
as natural or artificially synthesized. Most natural peptides are from animals, plants, and microorganisms. Both natural and synthetic
peptides can be produced through chemical synthesis, biological fermentation, gene recombination and other methods. Peptides are ubiquitous
in living organisms and modulate many physiological processes, making them a common research subject in medicine, cosmetics, and agriculture. 12

 Broad-Spectrum Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes

 Id.

 Science Direct – Advanced Agrochem: Volume 2, Issue 1, March 2023, Pages 58-78, Peptides, new tools for plant
protection in eco-agriculture. Yi-Meng Zhang, De-Xing Ye, Yan Liu, Xin-Yuan Zhang, Yuan-Lin Zhou, Li Zhang, Xin-Ling Yang.

 How
do Peptides Work Against Diseases?

 Through
seed traits, plant seeds are genetically coded to produce AMPs. Upon encountering a disease microbe, AMPs penetrate the cell wall of
the target disease microbe, causing the contents of the disease microbe to spill out, destroying the disease cell. The same effect is
foreseen in the utilization of the topical spray.

 Delivery
by Transgenic Seed Traits

 In
North America, the seed trait market is currently estimated to exceed $10 billion. The adoption of crop seeds with enhanced traits has
been staggering with over 75% of U.S. corn, cotton and soybeans being produced using seeds with enhanced traits. 13

 The following image shows corn with Genvor's seed traits, which is
currently growing in a USDA facility for study:

 Corn
with Genvor Seed Traits Growing in USDA Facility for Study

 Delivery
by Topical Spray (Bio-fungicide)

 The
rising global demand for organic foods, the trend in the reduction of chemical residues, stricter import and supermarket standards, shorter
pre-harvest intervals, a push for sustainability, growing food scarcity, the phase out of synthetic agricultural chemicals, along with
the market's demand for additional modes of action to manage resistance, has resulted in biologicals being one of the fastest-growing
sectors in the crop protection market, increasing at twice the compound annual growth rate of the crop protection market as a whole. 14
 The global agricultural biologicals market was approximately $9.5 billion in 2019 and is expected to grow to approximately $19.7
billion by 2026. 15 Unlike synthetic chemicals, bio-fungicides are derived from configurations of amino acids and proteins
occurring in nature; therefore they do not contaminate soil, water, turf, beneficial insects, birds, fish, and non-targeted plants.

 14

 15 Id.

 16 Id.

 USDA
Partnership – Benefits of a CRADA

AMPs gained the attention of the USDA in its pursuit of solutions for plant disease in corn, the U.S.'s largest crop. Based on
over 30 years of research by Genvor founder Dr. Jesse Jaynes, Genvor was awarded a Cooperative Research and Development Agreement ("CRADA")
in 2018 to develop and commercialize disease resistance and nutritional enhancement in corn seed based upon Genvor's proven technology.
A CRADA expands expertise and speeds development of many technologies that are now used by farmers or found in the grocery store through
access to USDA resources such as advanced laboratories, increasing the chances that research outcomes are adopted commercially to maximize
impact, driving a significantly lower overhead rate than a university's research program, and creating a multi-disciplinary research
team to increase technical breadth and depth of the lab. In addition, a CRADA provides access to the USDA regulatory team for registrations
and processes.

Peptides are proven effective in corn seed traits.

 As
a result of the USDA and Genvor partnership through the CRADA, the effectiveness of Genvor's solutions in protecting against Aflatoxins
in corn seed has been established, with the probability that this technology can effectively be applied to other crop types. 17 Genvor
is expecting an extension of the CRADA to continue the studies of Genvor's 4 th generation of its peptides (GNV-185 and
GNV-187) towards commercialization. The Company now has the technology to move its superior AMPs from the research lab and greenhouse
to the field, with the goal of commercially producing Genvor's AMPs at a desirable price point for cost-effective and broad-based
agricultural use.

 What
is a USDA CRADA Worth to Genvor?

 In
the United State, it often takes eight years and $136 million to develop and bring a new seed trait through regulatory to the
marketplace. 18 The value of a CRADA, utilizing the USDA's existing labs, know-how, research, fields, greenhouses,
and oversight to develop a Seed Trait for corn, is significant as it allows Genvor to bring seed traits to market with substantially
less capital investment. For its CRADA in corn, Genvor's contribution was under $700,000, primarily for a dedicated scientist
to work onsite at the USDA facility over the years. Genvor is expecting to continue R&D of its anti-microbial and nutritional
enhancement peptides ("NEPs") for poultry and swine feed through additional CRADAs with the USDA. In addition, Genvor is
planning to apply for a CRADA for Aflatoxins in peanuts. The USDA partnership is based upon the confidence and proof of concept
found in Genvor's solutions.

 Below is a chart showing the average surveyed development costs of bringing
a new plant trait to market in the United States:

 Business
Strategy: Licensing First and Leveraging R&D with Third Parties

business model is to remain capital-light, focused on leveraging its third-party research and development through its initial CRADA with
the USDA, and any subsequent CRADAs that may be granted, while also adopting a licensing approach to reduce "cash burn" or
the need for significant manufacturing and marketing overhead. Genvor is highly scalable and capital efficient with minimal overhead
relative to peers, allowing the Company to focus on core research and development competency. Genvor does not expect revenue until the
end of 2025, through the licensing and distribution of either or both the topical spray and seed trait, utilizing licensing and royalty
opportunities.

 Citrus
Licensing with Royalty

has established an initial licensing and royalty agreement with Southern Gardens Citrus, a division of U.S. Sugar, operating 6,600 acres
of orange groves in Florida, utilizing Genvor's AGM-176 and AGM-179 peptides, proving the effectiveness of these peptides on the
crippling problems of canker on citrus crops. While 5+ years of studies showed the effectiveness of Genvor's AGM-176 and AGM-179,
Southern Gardens has not yet taken the usage of these solutions through regulatory approval for commercialization, which should generate
royalty revenue to Genvor following receipt of such approval.

 17 Broad-Spectrum
Antimicrobial Activity of Synthetic Peptides GV185 and GV187, Rebecca R. Sweany, Jeffrey W. Cary, Jesse M. Jaynes and Kanniah Rajasekaran,
March 20, 2023.

 18

 Discussions
with Additional Third-Party Crop Growers

is in discussions with other major growers of other crop types regarding the potential funding of Genvor's costs of research and
development through to seed traits, topical spray, or both – all as a solution to fight toxins, bacteria or fungi that damage various
spectrums of crop types. A licensing and royalty agreement with those growers are likely outcomes of any R&D funding agreement.

 Financing
Needs

is currently exploring financing options to generate the cash needed to pay for overhead, marketing, and production of peptides
to be used in R&D, contributions to the CRADA and regulatory costs to take existing technology through the process. Additional
financing may be required in the event self-funded R&D is needed. There are no plans currently to create Genvor's own labs,
greenhouses or fields or its research with the availability of utilizing existing labs, scientific and regulatory professionals –
chiefly through its CRADA with the USDA.

 Competition

 Below
are some of Genvor's agriscience competitors.

 Invaio
Sciences - Peptide maSAMP ( is used to control citrus Huanglongbing, a destructive disease.

 Plant
Health Care - PREtec technology ( from the American Plant Health Care (PHC) company, was patented
in the United States in 2019. Its unique immune-inducing peptides and its mixtures with other products have been recognized for strengthening
plant resistance to disease and stress, as well as promoting plant growth. All PREtec peptides are variants of natural proteins and break
down rapidly in the environment, leaving no harmful residues on the crop or in the environment. In 2021, PHC launched PHC279 with PREtec
technology in Brazil and sold it under the name of Saori. This product is used as a seed treatment to prevent Asian soybean rust.

 PHYTOTECH
LABS FLG22 ( from Phytotech, induces the natural immune response. Its sequence was derived from the highly
conserved N-terminal region of Pseudomonas aeruginosa flagellin. FLG22 and its derivatives induce defense responses in Lycopersicon esculentum
and Arabidopsis thaliana and have elicitor activity. Many immune induction peptides are in development.

 CEV,
SA (CEV) ( established in 2006 with the objective of developing a new patented protein-based bio-fungicide. The
active ingredient is a polypeptide, named BLAD, which is extracted from the germinated seeds of lupines. BLAD's multi-site targets
cell walls, cell membrane and cell metabolism.

 Syngenta
Global  Syngenta is a world market leader in crop protection products, developing and producing herbicides,
insecticides, fungicides and seed treatment products for farmers and growers.

 Hello
Nature -  offers a range of biotechnological and certified solutions for modern and sustainable agriculture
including natural bio-stimulants of vegetal origin, beneficial microbials and organic fertilizers.

 Sym
Agro -  serves horticultural and agricultural specialty markets with an assortment of fertilizers, fungicides,
biologics, and pesticides. ProBlad Verde fungicide is available in the US for use on a variety of crops, including stone fruit,
cane berries, strawberries, pome fruits, grapes, almonds, leafy greens, herbs, and tomatoes.

 Innatrix
– Products under development in their pipeline: InnaLB (Potato Late Blight) - Peptide product to stop late blight infection,
by interfering with critical late blight effectors, InnaNema (Soybean Cyst Nematode) Seed treatment product to stop nematode infection
and reproduction process on soybean roots, by RNAi technology, and nnaHLB (Citrus Greening) Peptide product to stop citrus greening
infection by interfering with critical citrus greening effector.

 The
following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included
in this Form 10-K.

 COMPARISON
OF THE YEAR ENDED SEPTEMBER 30, 2023, TO THE NINE MONTHS ENDED SEPTEMBER 30, 2022

 Results
of Operations

 The
following discussion and analysis of our consolidated financial condition and results of operations should be read in conjunction
with the consolidated financial statements and notes thereto for the year ended September 30, 2023, and the nine months ended
September 30, 2022, and related management discussion herein.

 Our
consolidated financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting
principles of the United States ("GAAP").

 Going
Concern Qualification

 Several
conditions and events cast substantial doubt about the Company's ability to continue as a going concern. As of September 30, 2023,
the Company had an accumulated deficit of $17,719,307, incurred a net loss of $1,707,481 for the year ended September 30, 2023, requires
capital for contemplated operational activities to take place. These conditions raise substantial doubt about the Company's ability
to continue as a going concern. Management's plans with respect to operations include raising additional capital through sales
of equity or debt securities as may be necessary to pursue such business plans and sustain operations until such time as the Company
can merge with or be acquired by another entity. However, there can be no assurance that management will be successful in obtaining additional
funding or in attaining profitable operations. The ability to successfully resolve these factors raises substantial doubt about the Company's
ability to continue as a going concern.

 Our
operating results for the year ended September 30, 2023, and the nine months ended September 30, 2022, and the changes between those
periods for the respective items, are summarized as follows:

 Year
 Ended
 30,
 2023

 Nine
 Months Ended September 30,
 2022

 Operating loss

 $
 (1,438,686
)

 $
 (4,063,881
)

 Total other income (expense)

 (268,795
)

 (176,228
)

 Net loss

 $
 (1,707,481
)

 $
 (4,240,109
)

 Revenues

 We
did not earn any revenues during the years ended September 30, 2023, or 2022.

 Operating
Loss

 Our
loss from operations decreased to $1,438,686 during the year ended September 30, 2023, from an operating loss of $4,063,881 in the nine
months ended September 30, 2022. The following table presents operating expenses for the year ended September 30, 2023, and the nine
months ended September 30, 2022:

 Year
 Ended
 30,
 2023

 Nine
 Months Ended September 30,
 2022

 Professional fees

 $
 377,329

 $
 233,153

 Payroll related expenses

 171,856

 284,746

 Research and development

 -

 -

 Stock-based compensation

 977,235

 3,512,500

 Depreciation expense

 1,832

 1,374

 General and administrative
 expenses

 (89,566
)

 32,108

 Total Operating Expenses

 $
 1,438,686

 $
 4,063,881

 We
realized an increase in professional fees during the year ended September 30, 2023, as compared to the nine months ended September
30, 2022 primarily as a result of increased accounting, audit, and legal expenses incurred during 2023. Stock-based compensation
expenses decreased during the year ended September 30, 2023, as compared to the nine months ended September 30, 2022 primarily as a
result of the issuance of shares of common stock.

 Net
Loss

 The
Company incurred a net loss of $1,707,481 during the year ended September 30, 2023, as compared to a net loss of $4,240,109 during the
nine months ended September 30, 2022, because of the increased operating expenses during 2022 described above.

 Liquidity
and Capital Resources

 Based
upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve
months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures
or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There
can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation
of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable
terms or at all.

 Working
Capital

 The
following table presents our working capital position as of September 30, 2023, and 2022:

 30, 2023

 30, 2022

 Cash

 $
 44,354

 $
 296,386

 Current Assets

 66,329

 298,386

 Current Liabilities

 1,787,059

 1,621,174

 Working Capital (Deficiency)

 $
 (1,720,730
)

 $
 (1,569,268
)

 The
increase in working capital deficiency as of September 30, 2023 as compared to September 30, 2022, was primarily due to the USDA CRADA
liability decreasing from $246,400 as of September 30, 2022, to $0 as of September 30, 2023, increases in accounts payable and accrued
expenses from $270,178 as of September 30, 2022 to $388,809 as of September 30, 2023, partially offset by the decrease in current assets
as of September 30, 2023, as compared to September 30, 2022.

 Cash
Flow

 We
fund our operations with cash received from issuances of promissory notes and equity as described below.

 Cash
Flows from Operating Activities

 We
did not generate cash flows from operating activities for the year ended September 30, 2023, or for the nine months ended September 30,
2022. For the year ended September 30, 2023, and the nine months ended September 30, 2022, net cash used in operating activities were
$871,734 and $553,236, respectively.

 Cash
Flows from Investing Activities

 For
the year ended September 30, 2023, and the nine months ended September 30, 2022, no cash flows were provided by or used in investing
activities.

 Cash
Flows from Financing Activities

 For
the year ended September 30, 2023, and the nine months ended September 30, 2022, $619,702 and $465,000, respectively, in net cash was
provided by financing activities. For the year ended September 30, 2023, and the nine months ended September 30, 2022, $265,000 and $300,000,
respectively, in cash was provided by notes payable, and $354,702 and $165,000, respectively, in net cash was provided by sales of common
stock.

 Off-Balance
Sheet Arrangements

 The
Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on
the Company's consolidated financial condition, changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that are material to investors.

 Critical
Accounting Policies

 Use
of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States
of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements
include the amortization period for intangible assets, valuation and impairment valuation of intangible assets, depreciable lives of
the web site and property and equipment, valuation of warrant and beneficial conversion feature debt discounts, valuation of share-based
payments and the valuation allowance on deferred tax assets.

 Investments
in Equity

 We
measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with
the change in fair value included in net income. We use quoted market prices to determine the fair value of equity securities with readily
determinable fair values. For equity securities without readily determinable fair values, we have elected the measurement alternative
under which we measure these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes
in orderly transactions for the identical or a similar investment of the same issuer. Management assesses each of these investments on
an individual basis.

 Item
7A. Quantitative and Qualitative Disclosures about Market Risk

 As
the Company is a "smaller reporting company," this item is inapplicable.

 Item
8. Financial Statements and Supplementary Data

 Table
of Contents

 Page

 Report of Independent Registered Public Accounting Firm (PCAOB ID: 76)

 Consolidated Balance Sheets as of September 30, 2022 and 2022

 Consolidated Statements of Operations for the year ended September 30, 2023, and for the nine months ended September 30, 2022

 Consolidated Statements of Changes in Stockholders' Deficit for the year ended September 30, 2023 and for the nine months ended September 30, 2022

 Consolidated Statements of Cash Flows for the year ended September 30, 2023 and for the nine months ended September 30, 2022

 Notes to Consolidated Financial Statements

 F- 1

 Your
Vision Our Focus

 Report
of Independent Registered Public Accounting Firm

 Board
of Directors and Shareholders

 Opinion
on the Consolidated Financial Statements

 We
have audited the accompanying consolidated balance sheets of Genvor Incorporated as of September 30, 2023 and 2022, and the related consolidated
statements of operations, changes in stockholders' deficit, and cash flows for the year ended September 30, 2023 and the nine months
ended September 30, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Genvor Incorporated
as of September 30, 2023 and 2022, and the consolidated results of its operations and its cash flows for the year ended September 30,
2023 and the nine months ended September 30, 2022, in conformity with accounting principles generally accepted in the United States of
America.

 Going
Concern

 The
accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed
in Note 1 to the consolidated financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency
that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are
also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of
this uncertainty.

 Basis
for Opinion

 These
consolidated financial statements are the responsibility of the entity's management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) ("PCAOB") and are required to be independent with respect to Genvor Incorporated in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Genvor Incorporated is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose
of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express
no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.

 /s/
 Turner, Stone & Company, L.L.P.

 We
have served as Genvor Incorporated's auditor since 2020.

 Dallas,
Texas

 December
22, 2023

 F- 2

 Consolidated Balance Sheets

30,

 2023

 2022

 ASSETS

 Current assets:

 Cash

 $
 44,354

 $
 296,386

 Prepaid expenses

 21,975

 -

 Other
 current assets

 -

 2,000

 Total current assets

 66,329

 298,386

 Fixed assets, net

 15,734

 17,565

 Total assets

 $
 82,063

 $
 315,951

 LIABILITIES AND STOCKHOLDERS'
 DEFICIT

 Current liabilities:

 Convertible notes payable

 $
 1,319,500

 $
 1,052,000

 Accounts payable and accrued
 expenses

 388,809

 270,178

 Due to related party

 30,000

 3,846

 SBA loan

 48,750

 48,750

 USDA
 CRADA liability

 -

 246,400

 Total current liabilities

 1,787,059

 1,621,174

 Non-current liabilities:

 Convertible
 notes payable, net of discounts

 -

 89,221

 Total non-current liabilities

 -

 89,221

 Total liabilities

 1,787,059

 1,710,395

 Commitments and contingencies (Note 6)

 Stockholders' deficit:

 Preferred stock, $ 0.001 par value, 20,000,000
 shares authorized

 Preferred stock - series
 A, 10 shares authorized, 6 and 9 shares issued and outstanding as of September 30, 2023, and 2022, respectively

 -

 -

 Preferred stock - series
 B, 2,500,000
 shares authorized, 2,060,536
 and 0
 shares issued as of September 30, 2023, and 2022, respectively, 1,558,024
 and 0
 outstanding as of September 30, 2023, and 2022, respectively

 2,061

 -

 Preferred stock value

 Common stock, $ 0.001 par
 value, 300,000,000 shares authorized, 19,061,936 and 38,678,155 shares issued, issuable and outstanding as of September 30, 2023,
 and 2022, respectively

 19,062

 38,678

 Treasury stock, 502,512 and 0 shares of series B preferred stock at September 30, 2023,
and 2022, respectively

)

 -

 Additional paid-in capital

 16,293,188

 14,608,815

 Accumulated
 deficit

 ( 17,719,307
)

 ( 16,041,937
)

 Total stockholders'
 deficit

 ( 1,704,996
)

 ( 1,394,444
)

 Total liabilities and
 stockholders' deficit

 $
 82,063

 $
 315,951

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 3

 Consolidated Statements of Operations

 Nine Months

 Year Ended

 Ended

 30,

 30,

 2023

 2022

 Revenue

 $
 -

 $
 -

 Operating expenses

 Professional
 fees

 377,329

 233,153

 Payroll related expenses

 171,856

 284,746

 Research and development

 -

 -

 Stock-based compensation

 977,235

 3,512,500

 Depreciation expense

 1,832

 1,374

 Other general and administrative
 expenses

 ( 89,566
)

 32,108

 Total operating expenses

 1,438,686

 4,063,881

 Operating loss

 ( 1,438,686
)

 ( 4,063,881
)

 Other income (expense)

 Interest expense

 ( 43,795
)

 ( 51,117
)

 Loss on debt settlement

 ( 105,000
)

 ( 5,000
)

 Late fee capitalized into notes payable

 ( 120,000
)

 ( 90,000
)

 Amortization of debt discount

 -

 ( 30,111
)

 Total other expense, net

 ( 268,795
)

 ( 176,228
)

 Net loss

 $
 ( 1,707,481
)

 $
 ( 4,240,109
)

 Basic and diluted net loss per common share

 $
 ( 0.07
)

 $
 ( 0.13
)

 Basic and diluted weighted average common shares
 outstanding

 19,545,725

 32,437,505

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 4

 Consolidated
Statements of Changes in Stockholders' Deficit

 For
the Year Ended September 30, 2023, and the Nine Months Ended September 30, 2022

 Stock

 Capital

 Deficit

 Total

 Series A

 Series B

 Additional

 Accumu-

 Preferred Stock

 Preferred Stock

 Treasury

 Paid-in

 lated

 Stock

 Capital

 Deficit

 Total

 Balance, December 31, 2021

 -

 $
 -

 -

 $
 -

 26,025,020

 $
 26,025

 $
 -

 $
 9,538,772

 $
 ( 11,801,828
)

 ( 2,237,031
)

 Common stock issued for services

 -

 -

 -

 -

 6,525,000

 6,525

 -

 3,505,700

 -

 3,512,225

 Common stock issued for cash

 -

 -

 -

 -

 305,000

 -

 164,970

 165,275

 Common stock issued for debt conversion

 -

 -

 -

 -

 2,622,647

 2,622

 -

 1,232,933

 -

 1,235,555

 Payment for reverse capitalization

 -

 -

 -

 -

 -

 -

 -

 ( 150,000
)

 -

 ( 150,000
)

 419 fund raising services

 -

 -

 -

 -

 170,000

 -

 ( 170
)

 -

 -

 Founder shares issued

 -

 -

 -

 -

 1,855,888

 1,856

 -

 ( 1,856
)

 -

 -

 Issuance of common stock for note receivable

 -

 -

 -

 -

 99,600

 -

 ( 100
)

 -

 -

 Issuance of common stock for 2021 SPA

 -

 -

 -

 -

 50,000

 -

 ( 50
)

 -

 -

 Common stock issued to prior S-1 investors

 -

 -

 -

 -

 975,000

 -

 48,750

 -

 49,725

 Issuance of common stock for settlements

 -

 -

 -

 -

 50,000

 -

 ( 50
)

 -

 -

 Beneficial conversion feature

 -

 -

 -

 -

 -

 -

 269,916

 -

 269,916

 Net loss for the period ended September 30, 2022

 -

 -

 -

 -

 -

 -

 -

 -

 ( 4,240,109
)

 ( 4,240,109
)

 Balance, September 30, 2022

 -

 $
 -

 -

 $
 -

 38,678,155

 $
 38,678

 $
 -

 $
 14,608,815

 $
 ( 16,041,937
)

 $
 ( 1,394,444
)

 Balance, September 30, 2022

 -

 $
 -

 -

 $
 -

 38,678,155

 $
 38,678

 $
 -

 $
 14,608,815

 $
 ( 16,041,937
)

 $
 ( 1,394,444
)

 Beginning balance value

 -

 $
 -

 -

 $
 -

 38,678,155

 $
 38,678

 $
 -

 $
 14,608,815

 $
 ( 16,041,937
)

 $
 ( 1,394,444
)

 Retrospective adoption of ASU 2020-06

 -

 -

 -

 -

 -

 -

 -

 ( 210,779
)

 30,111

 ( 180,668
)

 Issuance of Series A preferred stock

 -

 -

 -

 -

 -

 -

 -

 -

 -

 Conversion of common stock into Series B preferred stock

 -

 -

 2,060,536

 2,061

 ( 20,605,334
)

 ( 20,605
)

 -

 18,544

 -

 -

 Sale of common stock

 -

 -

 -

 -

 735,000

 -

 361,790

 -

 362,525

 Conversion of note payable into common stock

 -

 -

 -

 -

 122,115

 -

 78,511

 -

 78,633

 Conversion of notes payable into warrants

 -

 -

 -

 -

 -

 -

 -

 354,114

 -

 354,114

 Issuance of warrants for services

 -

 -

 -

 -

 -

 -

 -

 962,900

 -

 962,900

 Conversion of liabilities into common stock

 -

 -

 -

 -

 32,000

 -

 19,303

 -

 19,335

 Issuance of common stock for legal settlement

 -

 -

 -

 -

 100,000

 -

 99,990

 -

 100,090

 Return of treasury stock

 ( 3
)

 -

 ( 502,512
)

 -

 -

 -

)

 -

 -

)

 Net loss for the period ended September 30, 2023

 -

 -

 -

 -

 -

 -

 -

 -

 ( 1,707,481
)

 ( 1,707,481
)

 Balance, September 30, 2023

 $
 -

 1,558,024

 $
 2,061

 19,061,936

 $
 19,062

 $
)

 $
 16,293,188

 $
 ( 17,719,307
)

 $
 ( 1,704,996
)

 Ending balance value

 $
 -

 1,558,024

 $
 2,061

 19,061,936

 $
 19,062

 $
)

 $
 16,293,188

 $
 ( 17,719,307
)

 $
 ( 1,704,996
)

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 5

 Consolidated Statements of Cash Flow

 Nine

 Year

 Months

 Ended

 Ended

 2023

 2022

 Cash flows from operating activities:

 Net loss

 $
 ( 1,707,481
)

 $
 ( 4,240,109
)

 Adjustments to reconcile net loss to net cash used in operating activities:

 Depreciation expense

 1,832

 1,374

 Stock-based compensation

 977,235

 3,512,500

 Conversion of liabilities into common stock

 19,335

 -

 Late fee capitalized into notes payable

 120,000

 90,000

 Loss on debt settlement

 105,000

 5,000

 Common stock issued for interest expense

 6,447

 -

 Effects of the elimination of the beneficial conversion feature

 150,556

 -

 Beneficial conversion feature

 -

 30,111

 Changes in assets and liabilities:

 Prepaid expenses

 ( 21,975
)

 1,331

 Prepaid costs for reverse capitalization

 -

 Other current assets

 2,000

 ( 2,000
)

 Receivables from related parties

 -

 2,053

 Accounts payable and accrued expenses

 ( 304,437
)

 139,139

 USDA CRADA liability

 ( 246,400

)

 -

 Due to related party

 26,154

 3,846

 Net cash used in operating activities

 ( 871,734
)

 ( 553,235
)

 Cash flows from financing activities:

 Proceeds from notes payable

 265,000

 300,000

 Proceeds from sale of common stock

 354,702

 165,000

 Net cash provided by financing activities

 619,702

 465,000

 Net decrease in cash

 ( 252,032
)

 ( 88,235
)

 Cash at beginning of period

 296,386

 384,621

 Cash at end of period

 $
 44,354

 $
 296,386

 Cash paid for interest

 $
 -

 $
 -

 Cash paid for taxes

 $
 -

 $
 -

 Non-cash investing and financing activities:

 Discount on notes payable

 $
 -

 $
 269,916

 Conversion of note payable into common stock

 $
 76,325

 $
 1,235,555

 Conversion of liabilities into common stock

 $
 19,303

 $
 -

 Conversion of notes payable into warrants

 $
 350,000

 $
 -

 Issuance of common stock for debt settlement

 $
 -

 $
 49,725

 Fundraising services

 $
 -

 $
 170,000

 Fund

 $

 -

 $

 -

 Prepaid costs for reverse capitalization recognized in additional paid-in capital

 $
 -

 $

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 6

 Notes
to Consolidated Financial Statements

30, 2023

 NOTE
1 – ORGANIZATION AND BASIS OF PRESENTATION

 Company
Background

 On
May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the "Company" or "Genvor" or "we"),
a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"),
and Genvor Inc., a Delaware corporation ("Old Genvor"), completed their previously announced merger transaction pursuant
to which the Company acquired Old Genvor (the "Acquisition"), and Old Genvor became a wholly-owned subsidiary of the Company.
The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the "Acquisition Agreement"),
pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock
would be exchanged for a share of the Company's common stock, and a merger agreement, dated March 2, 2022 (the "Merger Agreement"),
pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company
and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company
(the "Merger"). After closing of the Merger, the Company was renamed "Genvor Incorporated". Genvor develops plant-based
defense technology designed to help farmers achieve global food security.

May 2019, Old Genvor acquired Nexion Biosciences LLC ("NBLLC") from a founder for nominal consideration as a wholly owned
subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018. The consolidated financial statements of the Company include
the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been
eliminated upon consolidation.

 Nature
of Operations

 The
Company's business plan is that Genvor will be continuing its research and development addressing plant-based defense technology
ich then can be commercialized to help farmers and growers globally to overcome potentially catastrophic losses resulting from plant
disease, toxins, bacteria, and fungi that destroy their crops. These solutions can result in greater crop yields and economic savings,
which can assist in overcoming world-wide food scarcity.

 Basis
of Presentation

 The
Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America
("US GAAP") and has a year-end of September 30. The wholly owned subsidiary has a year-end of December 31.

 Due
to the change in fiscal year-ends, the consolidated financial statements will reflect the balance sheets and the statements of changes
in stockholders' deficit dates of September 30, 2023, and September 30, 2022, whereas the statements of operations and statements
of cash flows are for the year ended September 30, 2023, and the nine months ended September 30, 2022.

 Principles
of Consolidation

 The
consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances
and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance
with US GAAP and stated in United States dollars, have been prepared
by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

 F- 7

 Liquidity
and Going Concern

 The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2023,
the Company had an accumulated deficit of $ 17,719,307. For the year ended September 30, 2023, the Company recognized a net loss of $ 1,707,481
and had net cash used in operating activities of $ 871,734, with no revenues earned, and limited operational history. These matters, among
others, raise substantial doubt about the Company's ability to continue as a going concern.

 While
the Company is currently developing its products and technologies, the Company's cash position may not be significant enough to
support the Company's daily operations. Management intends to raise additional funds by way of additional public and/or private
offerings of its stock. Management believes that the actions presently being taken to further implement its business plan, develop its
products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern. While
the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds in the future,
there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's
ability to further implement its business plan and generate cash flows from financing activities or operating activities. The financial
statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 Use
of Estimates

 The
preparation of financial statements in conformity with US GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent
liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.

 Cash
Flow Reporting

 The
Company follows Accounting Standards Codification ("ASC 230"), Statement of Cash Flows, for cash flow reporting,
classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides
definitions of each category, and uses the indirect or reconciliation method ("indirect method") as defined by ASC 230,
to report net cash flow from operating activities by adjusting net income or loss to reconcile it to net cash flow from operating
activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected
future operating cash receipts and payments and (b) all items that are included in net income or loss that do not affect operating
cash receipts and payments.

 Cash

 Cash
is comprised of cash balances. Cash is held at major financial institutions and is subject to credit risk to the extent that those balances
exceed applicable Federal Deposit Insurance Corporation ("FDIC") insurance amounts of $ 250,000. From time to time, the Company
has certain cash balances, including restricted cash, that may exceed insured limits. The Company utilizes large banking institutions
that are reputable, therefore mitigating the risks.

 The
Company maintains its cash balances at one financial institution that is insured by the FDIC. At September
30, 2023, the Company's cash balances were not in excess of federally insured limits.

 Fixed
Assets

 Fixed
assets are comprised of furniture and equipment which are stated at cost. Depreciation is provided by the straight-line method over
the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed
as incurred.

 F- 8

 Stock-Based
Compensation

 The
Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation,
and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date
fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately
expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 The Company measures compensation cost for all employee
stock-based awards at their fair values on the date of grant. Stock-based awards issued to non-employees are measured at their fair values
on the date of grant and are re-measured at each reporting period through their vesting dates, as applicable. The fair value of stock-based
awards is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method.

 Fair
Value of Financial Instruments

 The
book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature
of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs)
and an entity's own assumptions (unobservable inputs).

 The
hierarchy consists of three levels

 Level
 one — Quoted market prices in active markets for identical assets or liabilities;

 Level
 two — Inputs other than level one inputs that are either directly or indirectly observable; and

 Level
 three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect
 those assumptions that a market participant would use.

 Determining
which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures
each quarter.

 Financial
Instruments

 The
Company's financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term
notes payable and are accounted for under the provisions of ASC 825, Financial Instruments. The carrying amount of these financial
instruments, as reflected in the accompanying consolidated balance sheets approximates fair value.

 Long-lived
Assets

 The
Company's long-lived assets and other assets (consisting of furniture, equipment, and a patent) are reviewed for impairment in
accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial
Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in
circumstances indicate that the carrying amount of the asset may not be recoverable. The recoverability of an asset to be held and
used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the asset. If such an asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the
carrying amount of the asset exceeds its fair value. Impairment evaluations involve management's estimates on asset useful
lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management, which could
have a material effect on our reporting results and financial positions. Fair value is determined through various valuation
techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered
necessary. During the year ended September 30, 2023, and the nine months ended September 30, 2022, the Company had not experienced
impairment losses on its long-lived assets.

 Research
and Development

 The
Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional
service costs associated with the development of plant-based defense technology products. For the year ended September 30, 2023,
and the nine months ended September 30, 2022, the Company had $ 0 and $ 0 in research and development expenses, respectively.

 F- 9

 Patents

 Any
patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative
expenses in the statement of operations.

 Purchased
patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360,

 Income
Taxes

 The
Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets
and liabilities and loss carryforwards and their respective tax bases.

 Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those
temporary differences are expected to be recovered or settled.

 The
effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation
allowance is recorded when it is "more likely-than-not" that a deferred tax asset will not be realized.

 Tax
benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a
position taken on an income tax return. The Company has no liability for uncertain tax positions as of September 30, 2022. Interest
and penalties, if any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any
accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during
the nine months ended September 30, 2022.

 Loss
Per Share of Common Stock

 Basic
net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share
("EPS") include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of
stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per
share when the Company reports a loss because to do so would be anti-dilutive for the periods presented. The Company had total
potential additional dilutive securities outstanding at September 30, 2023 and 2022 of $ 500,000
and $ 300,000,
respectively.

 Recent
Accounting Pronouncements

 In
August 2020, the FASB issued Accounting Standards Updates ("ASU") 2020-06, Debt with Conversion and Other
Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC
470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how
convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years
beginning after December 15, 2021. The Company evaluated the impact of ASU 2020-06 on its consolidated financial statements as it
was adopted in 2022 and the impact can be seen on the Consolidated Statements of Changes in Stockholders' Deficit as it affected additional paid-in capital,
$ 210,779, offset in accumulated deficit, $ 30,111.

 Recently
Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently
adopted would have a material effect on the accompanying consolidated financial statements.

 F- 10

 NOTE
3 – BORROWINGS

 Commercial
Loan

 On
April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program ("PPP") in
the principal amount of $ 48,750. The note bears interest at a variable rate of approximately 1 % and matured in April 2022; and it is
currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting
agreement salary between Nexion Biosciences, Inc., organized in the state of Florida ("NBFL") (a related party) and the CEO.

 Payable
for Patent

 Notes
Payable

 From
time to time, the Company's subsidiary, Genvor Inc., entered into unsecured notes payable with individual investors. Only Noteholder
E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 7). The terms of these notes are listed
below. Several of the notes are convertible into shares of the Company's common stock as detailed in the following schedule.

OF CONVERTIBLE NOTES PAYABLE

 Balance

 Convertible

 Interest

 Loan

 into

 Noteholder

 Origination

 Maturity

 Rate

 Balance

 Shares (c)

 Brent Lilienthal (a) (b)

 2019

 12/31/2021

 %

 $
 217,000

 N/A

 Mel Wentz (a) (b)

 03/19/2019

 04/29/2019

 %

 570,000

 N/A

 Kirk Huntsman (a)

 03/01/2019

 02/29/2020

 %

 32,500

 N/A

 John Hare (d)

 04/29/2019

 unspecified

 %

 300,000

 30,000

 Barkley Capital LLC

 09/13/2023

 03/13/2024

 %

 200,000

 134,000

 1,319,500

 164,000

 (d) Debt discount

 -

 $
 1,319,500

 (a)

 Past due at September 30, 2023

 (b)

 Amount owed in dispute

 (c)

 Convertible
 into common stock of the subsidiary, Genvor Incorporated

 (d)

 Debt discount

 The
notes do not have default provisions except for Mel Wentz receives a default penalty of $ 10,000 each month the note goes unpaid.

 The
Company is currently disputing amounts claimed to be owed to two noteholders, Brent Lilienthal, and Mel Wentz, under state usury
laws (See Note 6).

 On
September 13, 2023, the Company entered into a convertible promissory note with Barkley Capital LLC for $ 200,000. The note matures on
 March 13, 2024, and bears interest of 10 %. The note is convertible into 134,000 shares of common stock at a value of $ 1.50 per share.

the nine months ended September 30, 2022, $ 989,000 principal and $ 146,946 interest was converted into 2,316,147 common stock shares of
the Company. One note holder had a change in settlement terms, resulting in the recognition of $ 5,000 loss on debt settlement in the
accompanying statement of operations for the nine months ended September 30, 2022.

the year ended September 30, 2023, $ 76,325 was converted into 122,115
 common stock shares of the Company. Additionally,
$ 350,000
 principal and $ 4,114
 interest were converted into 1,400,000
 warrants for common stock of the Company.

 F- 11

 Interest
expense totaled $ 163,795 and $ 141,117, respectively, for the year ended September 30, 2023, and the nine months ended September 30, 2022,
including default penalties. Late fees totaled $ 120,000 and $ 90,000, respectively, for the year ended September 30, 2023, and the nine
months ended September 30, 2022. These late fees are in dispute and part of (a) and (b) above.

 NOTE
4 – STOCKHOLDERS' DEFICIT

 Preferred
Stock

 The
authorized preferred stock of the Company consists of 20,000,000 shares with a $ 0.001 par value.

 Series
A Preferred Stock

 On
August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock ("Series A"). Each share
of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation.
When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to
participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully
paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled
to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment
shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of
the Company).

 The
preferred stock was issued on August 16, 2022, as follows: Bradley White (former Chief Executive Officer), 3 shares; Dr. Clayton Yates
(Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

 On
September 28, 2023, as part of the Settlement Agreement with Bradley White (see Notes 6 and 7), Mr. White returned to the Company
for cancellation of 3
shares of Series A preferred stock.

 As
of September 30, 2023, and 2022, there were 6 and 9 shares of Series A preferred stock issued and outstanding, respectively.

 Series
B Preferred Stock

 On
October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock ("Series
B"). The designation authorized 2,500,000 shares of Series B. Each share of Series B shall have 10 votes on all matters submitted
to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company. See
Note 10.

 On
October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common
shares outstanding to reduce the outstanding common stock issued by the Company, as follows:

OF CONVERTED SHARES OF COMMON STOCK

 Name

 Common
 Exchanged

 Series B
 Issued

 Jaynes Investment LLC (a)

 2,000,000

 200,000

 ACT Holdings LLC (a)

 7,312,612

 731,262

 LASB Family Trust (a)

 3,800,112

 380,012

 Jesse Michael Jaynes (a)

 4,767,611

 476,762

 Bradley White (a)

 1,225,000

 122,500

 PJ Advisory Group

 1,500,000

 Total

 20,605,335

 2,060,536

 (a)

 Related
 parties

 F- 12

 The
conversion of the common stock into Series B was valued at par, respectively, offset to additional paid-in capital. Series B
is convertible into common stock into the original amount of common stock converted therefore there is no change in the amount of common
stock outstanding on a fully diluted basis.

 On
September 28, 2023, as part of the Settlement Agreement with Bradley White (see Notes 6 and 7), Mr. White returned to the Company
for cancellation of 502,512
shares of Series B preferred stock; however, the shares have not been canceled and are being held in treasury
stock.

 There
were 2,060,536 issued and 1,558,024
outstanding at September 30, 2023 and 0
shares as of September 30, 2022.

 Common
Stock

 The
authorized common stock of the Company consists of 300,000,000 shares with a $ 0.001 par value. All common stock shares are non-assessable
and have one vote per share.

 On
April 21, 2022, the Company issued 569 shares of common stock to an individual under a transfer and exchange agreement for a note receivable
held in NBFL (see Note 3). At the transfer date, the latest sale of common stock was at $ 0.50, accordingly the shares were valued at
$ 285, and the note was written off since NBFL has since dissolved.

 In
connection with the Merger (see Notes 1 and 8), the founding shareholders of the Company cancelled 18,144,112 shares of common stock,
retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements
of changes in stockholders' deficit within the line item "Retroactive application of recapitalization."

July 2022, the Company entered into a transfer and exchange agreement with an individual to issue 99,600 shares of common stock for the
note receivable held in NBFL. Since NBFL had minimal assets and was dissolved during the year ended December 31, 2019, the note receivable
was immediately written-off. Based on the latest SPA price per share, the stock was valued at $ 1.00 per share, or $ 99,600.

 On
September 8, 2022, the Company issued 100,000
shares of common stock to a prior Nexion contractor. This was regarding a claim against the predecessor management and the Company
opted as a settlement to issue the common stock.

Issued for Services

the year ended September 30, 2023, and the nine months ended September 30, 2022, the Company issued 0 and 751,500 shares of common stock,
respectively, for business advisory services received, valued at $ 0 and $ 325,750, respectively.

 On
February 18, 2022, the Company issued 20,000 shares of common stock, valued at $ 10,000 (based on the latest third-party sale of common
stock) to an investor for stock compensation. Additionally, 5,000 shares were issued to a debt holder as incentive, valued at $ 2,500
(based on the latest third-party sale of common stock), recorded in interest expense in the accompanying consolidated statement of operations
for the nine months ended September 30, 2022.

 On
March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued
valued at $ 3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the
accompanying consolidated statement of operations.

April 2022, the Company issued 5,000 shares of common stock to a consultant valued at $ 2,500 and recorded in stock compensation in the
accompanying consolidated statement of operations.

 On
May 27, 2022, the Company issued 500,000 shares of common stock for consulting services. Based on the latest third-party sale of common
stock, this resulted in $ 500,000 stock-based compensation.

 On
September 13, 2022, the Company issued 170,000 shares of common stock to Scott Gann for services.

 F- 13

 Stock
Issued for Cash

 From
October through December 2021, the Company entered into fourteen stock purchase agreements ("SPA") for the issuance of a
total of 1,475,020 shares of common stock at prices ranging from $ 0.40 -$ 0.50. The proceeds received under these SPAs totaled $ 570,005.

January and February 2022, the Company entered into six SPAs for the issuance of a total of 280,000 shares of common stock at $ 0.50.
The proceeds received under these SPAs totaled $ 140,000.

 On
May 12, 2022, the Company entered into an SPA for the issuance of 25,000 shares of common stock for $ 25,000, or $ 1.00 per share.

July 2022, the Company issued 975,000 common stock shares to the prior S-1 investors pursuant to their subscription agreements.

July 2022, the Company issued 50,000 shares of common stock to a shareholder pursuant to a December 2021 SPA.

 On
November 17, 2022, the Company issued 300,000 shares of common stock to an investor for $ 150,000.

 On
May 3, 2023, the Company issued 100,000 shares of common stock to an investor for $ 50,000.

 On
May 12, 2023, the Company issued 15,000 shares of common stock to an investor for $ 15,000.

 On
May 29, 2023, the Company issued 10,000 shares of common stock to an investor for $ 10,000.

 On
July 12, 2023, the Company issued 20,000 shares of common stock to an investor for $ 10,000.

 On
July 13, 2023, the Company issued 20,000 shares of common stock to an investor for $ 10,000.

 On
July 14, 2023, the Company issued 50,000 shares of common stock to an investor for $ 25,000.

 On July 14, 2023, the Company issued 4,665 shares of common stock for the
conversion of accrued interest of $ 2,333.

 On
July 17, 2023, the Company issued 25,000 shares of common stock to an investor for $ 10,000.

 On July 17, 2023, the Company issued 50,000 shares of common stock to an
investor for $ 25,000.

 On
August 25, 2023, the Company issued 50,000 shares of common stock to an investor for $ 25,000.

 On
September 16, 2023, the Company issued 75,000
shares of common stock for the settlement of a debt and accrued interest for $ 25,000.

 On
September 19, 2023, the Company issued 20,000 shares of common stock to an investor for $ 20,000.

 Other
Stock Issuances

 On
June 14, 2023, the Company issued 25,000 shares of common stock related to the conversion of a note payable for $ 12,500.

 On
July 1, 2023, the Company issued 29,665 shares of common stock related to the conversion of a note payable and accrued interest for $ 14,833.

 Stock
Options and Warrants

the year ended September 30, 2023, the Company issued 2,362,900 warrants for common stock of the Company. The issuance was for the following:

 - 162,900 warrants for common stock with an exercise price of $ 0.001, valued at $ 142,900

 by related party – 600,000 warrants for common with an exercise price of $ 0.001, valued
 at $ 600,000

 Settlement
 of debt – 200,000 warrants for common stock with an exercise price of $ 0.001, valued
 at $ 200,000

 Conversion
 of notes payable and accrued interest – 1,400,000 warrants for common stock with an
 exercise price of $ 0.001, valued at $ 359,414

 F- 14

 NOTE
5 – FEDERAL INCOME TAX

 As
of September 30, 2023, and 2022, the Company has net operating loss carry forwards of approximately $ 2,497,000
and $ 2,133,000,
respectively, which may be available to reduce future years' taxable income through 2043. The Company's net operating
loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses because of an
ownership change as defined in Section 382 of the Internal Revenue Code.

 The
Company's tax expense differs from the "expected" tax expense for Federal income tax purposes (computed by applying
the United States Federal tax rate of 21 % to loss before taxes for fiscal year 2023 and 2022), as follows:

OF INCOME TAX EXPENSE

 2023

 2022

 Tax expense (benefit) at the statutory rate

 $
 ( 101,591
)

 $
 ( 204,559
)

 State income taxes, net of federal income tax benefit

 ( 12,578
)

 ( 25,326
)

 Change in valuation allowance

 114,169

 229,885

 Total

 $
 -

 $
 -

 The
tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred
tax assets and liabilities.

 The
tax years 2023 and 2022 remain open for examination by federal agencies and other jurisdictions in which it operates.

 The
tax effect of significant components of the Company's deferred tax assets and liabilities at September 30, 2023 and 2022, are as
follows:

OF DEFERRED TAX ASSETS AND LIABILITIES

 2023

 2022

 Net operating loss carryforward

 $
 589,214

 $
 503,471

 Total gross deferred tax assets

 589,214

 503,471

 Less: Deferred tax asset valuation allowance

 ( 589,214
)

 ( 503,471
)

 Total net deferred taxes

 $
 -

 $
 -

 In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal
of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 Because
of the historical earnings history of the Company, the net deferred tax assets for 2023 and 2022 were fully offset by a 100% valuation
allowance. The valuation allowance for the remaining net deferred tax assets was $ 2,687,054 and $ 2,572,885 as of September 30, 2023,
and 2022, respectively.

 F- 15

 NOTE
6 – COMMITMENTS AND CONTINGENCIES

 From
time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in
any litigation that we believe could have a material adverse effect on its financial condition or results of operations.

 The
Company is currently disputing amounts claimed to be owed to two noteholders, Brent Lilienthal, and Mel Wentz, under state usury
laws (see Note 3).

 Subscription
Agreement and Cash Held in Escrow

 On
February 20, 2019, the Company entered into a subscription escrow agreement (the "Trust Agreement") with Branch Banking and
Trust Company ("BB&T"). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed
pursuant to the Company's prior Rule 419 S-1 offering. The balance held in trust at September 30, 2023 and 2022, totaled $ 19,705.

 Upon
completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering
during July 2022 and were released to the Company.

 Consulting
Agreements

the year ended September 30, 2023, and the nine months ended September 30, 2022, the Company paid the former CEO $ 171,856 and $ 284,746,
respectively, pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of
$ 150,000 which increases based on certain capital raise thresholds. At September 30, 2023 and 2022, accrued payroll owed to the CEO totaled
$ 0 and $ 0, respectively, as presented in the accompanying consolidated balance sheets.

 On
July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic
planning. The compensation pursuant to the agreement was $ 20,000 monthly. During the year ended September 30, 2023, and the nine months
ended September 30, 2022, $ 0 and $ 144,975, respectively, was paid to the consultant. During the nine months ended September 30,
2022, the Company issued 500,000 shares of common stock, valued at $ 325,750, to settle the amounts owed to the consultant (Note 4).

 On October
5, 2023, the Company entered into an Interim CEO & Executive Consultant Agreement (the " Executive Consulting
Agreement ") with Judith S. Miller, pursuant to which Judith S. Miller would serve as the Company's Interim CEO, and with
the Executive Consulting Agreement intended to be considered effective as of June 20, 2023, the date of Ms. Miller's original appointment
as Interim CEO of the Company. Under the Executive Consulting Agreement, which can be terminated at any time with or without cause by
the Company and upon 30 days' advance written notice by Ms. Miller, Ms. Miller will act as the Interim CEO of the Company and,
among other management duties, assist the Company in recruiting a full-time CEO and/or agricultural biotechnology management professional.
Following the appointment of a full-time CEO, Ms. Miller will be retained as an executive consultant for a period of 6 months thereafter.

 Office
Lease

 The
Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective
August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison,
Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on
its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms
of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would
not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $ 2,810 per month in addition to common area
maintenance charges. During the year ended September 30, 2023, and the nine months ended September 30, 2022, we incurred $ 10,187 and
$ 30,240, respectively, in office rental expenses.

 Research
and Development Agreement

September 2020, the Company assumed a Cooperative Research and Development Agreement ("CRADA") with the United States Department of Agriculture
("USDA"), Agricultural Research Service ("ARS"). Under this agreement, the Company committed to funding the remaining amount due. As of September
30, 2023, and 2022, $ 0 and $ 246,400, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets
as USDA CRADA liability.

 F- 16

 Settlement
Agreement

 On
September 28, 2023, the Company entered into a Settlement Agreement with Bradley White, former CEO and director of the Company, who
was terminated on June 20, 2023. As part of the Settlement Agreement, Mr. White was to receive a total settlement of $ 300,000,
payable in tranches of $ 50,000,
beginning on September 28, 2023, or within seven days, and each subsequent payment on the monthly anniversary of the Settlement
Agreement execution. In exchange for the settlement, Mr. White returned to the Company for cancellation of the following: 3
shares of Series A preferred stock and 502,512
shares of Series B preferred stock. See Notes 4 and 7.

 NOTE
7 – RELATED PARTY TRANSACTIONS

 Consulting Agreement

 On
October 5, 2023, the Company entered into an Interim CEO & Executive Consultant Agreement (the "Executive
Consulting Agreement") with Judith S. Miller, pursuant to which Judith S. Miller would serve as the Company's Interim
CEO, and with the Executive Consulting Agreement intended to be considered effective as of June 20, 2023, the date of Ms.
Miller's original appointment as Interim CEO of the Company. Under the Executive Consulting Agreement, which can be terminated
at any time with or without cause by the Company and upon 30 days' advance written notice by Ms. Miller, Ms. Miller will act
as the Interim CEO of the Company and, among other management duties, assist the Company in recruiting a full-time CEO and/or
agricultural biotechnology management professional. Following the appointment of a full-time CEO, Ms. Miller will be retained as an
executive consultant for a period of 6 months thereafter. For the year ended September 30, 2023, Ms. Miller has earned $ 65,000 of which $ 14,500 is a payable as of September
30, 2023.

 Share
Issuances to the Board of Directors

 On
March 8, 2022, the Company issued 2,000,000 shares of common stock to each of its three directors, for a total of 6,000,000 shares issued
valued at $ 3,000,000 (based on the latest third-party sale of common stock). The issuances are recorded in stock compensation in the
accompanying consolidated statement of operations.

 The
Company issued Series A preferred stock on August 16, 2022, as follows: Bradley White (former Chief Executive Officer), 3 shares; Dr.
Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares.
See Note 4.

 On
October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common
shares outstanding to reduce the outstanding common stock issued by the Company, as follows:

OF CONVERTED SHARES OF COMMON STOCK

 Name

 Common
 Exchanged

 Series B
 Issued

 Jaynes Investment LLC (a)

 2,000,000

 200,000

 ACT Holdings LLC (a)

 7,312,612

 731,262

 LASB Family Trust (a)

 3,800,112

 380,012

 Jesse Michael Jaynes (a)

 4,767,611

 476,762

 Bradley White (a)

 1,225,000

 122,500

 PJ Advisory Group

 1,500,000

 Total

 20,605,335

 2,060,536

 (a)

 Related
 parties

 On
September 28, 2023, as part of the Settlement Agreement, Bradley White returned for cancellation 3
shares of Series A preferred stock and 502,512
shares of Series B preferred stock.

from Related Parties

 The
daughter of the CEO and Board member was paid $ 21,900 and $ 16,925, respectively, for clerical services provided during the nine months
ended September 30, 2022, and the year ended December 31, 2021.

 Receivables
from Related Parties

2018, Robert Bubeck, former CEO, paid $ 3,846 of expenses on behalf of the Company. The amount due to related party at both September
30, 2023, and 2022 is $ 3,846 and is due on demand and non-interest bearing.

 F- 17

 Settlement
Agreement

 On
September 28, 2023, the Company entered into a Settlement Agreement with Bradley White, former CEO and director of the Company, who
was terminated on June 20, 2023. As part of the Settlement Agreement, Mr. White was to receive a total settlement of $ 300,000,
payable in tranches of $ 50,000,
beginning on September 28, 2023, or within seven days and each subsequent payment on the anniversary date of the Settlement
Agreement. In exchange for the settlement, Mr. White returned to the Company for cancellation of the following: 3
shares of Series A preferred stock and 502,512
shares of Series B preferred stock. See Notes 4 and 6.

 NOTE
8 – MERGER WITH OLD GENVOR

 On
May 27, 2022, the Company, formerly known as Allure Worldwide, Inc., Merger Sub, and Old Genvor completed the Acquisition and Merger
transaction (Note 1). The transaction was completed pursuant to the Merger Agreement, pursuant to which Merger Sub merged with and into
Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation in the Merger. Immediately
upon completion of the Merger, the former stockholders of Old Genvor stockholders held a majority of the common stock and voting interest
of the combined company.

 In
the Merger, the Company issued shares of its common stock to Old Genvor stockholders at an exchange ratio of 1:1 (with each share of
Old Genvor common stock automatically converted in the merger into the right to receive a share of Company common stock, and a total
of 35,261,871 shares of Company common stock issued to Old Genvor's pre-merger stockholders). Pursuant to the original Acquisition
agreement and Merger, the Company's founding shareholders retained 5 % of the Company's outstanding shares of common stock,
or 1,855,888 shares (Note 4). After closing the Acquisition and for a period of two years following commencement of trading of the Company's
common stock, the Company and Old Genvor agreed that the Company will make additional issuances of the Company's common stock to
the founding shareholders to ensure that in the aggregate they maintain their 5 % ownership of the Company's outstanding common
stock.

 Pursuant
to business combination accounting for reverse acquisitions, the Company accounted for the Merger as a capital transaction (reverse
recapitalization) rather than a business combination (or asset acquisition). Since the Company was formerly a special purpose
acquisition company ("SPAC") with no assets and only expenses related to maintaining its public shell company status, and Old Genvor
has cash, other assets, a contract with the USDA (Note 6), and has raised funds from investors, Old Genvor was determined to be the
accounting acquirer. Because a reverse recapitalization is equivalent to the issuance of shares by the private operating company for
the net monetary assets of the public shell company, the transaction costs incurred by Old Genvor to affect the recapitalization
were recognized as a reduction in additional paid-in capital rather than expensed as incurred. The assets and liabilities of Old
Genvor were consolidated with the Company at their book value, the equity accounts were retroactively adjusted to reflect the equity
of the Company, with a balancing adjustment through the additional paid-in capital account.

the nine months ended September 30, 2022, and the year ended December 31, 2021, the Company paid $ 140,000 and $ 10,000, respectively,
in anticipation of closing the Acquisition. The total $ 150,000 was recognized in additional paid-in capital as of the date of the Merger.

 NOTE
9 – INTELLECTUAL PROPERTIES

 The
Company was granted a patent (#11083775) on August 10, 2021, by the United States Patent and Trademark Office. The patent was assigned
by the inventors to the Company and The United States of America, as represented by the Secretary of Agriculture.

 NOTE
10 – SUBSEQUENT EVENTS

 The
Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to
disclose except the following.

 On
November 1, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 1, 2023, the Company issued 50,000 shares of common stock for $ 50,000.

 On
November 1, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 1, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 8, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 8, 2023, the Company issued 25,000 shares of common stock for $ 25,000.

 On
November 8, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 8, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 10, 2023, the Company issued 25,600 shares of common stock for $ 25,600.

 On
November 13, 2023, the Company issued 20,000 shares of common stock for $ 20,000.

 On
November 21, 2023, the Company issued 250,000 warrants for common stock to Good Works Funding, Inc., which may be deemed to be beneficially
owned by Judith S. Miller, a milestone on their consulting agreement.

 On
December 8, 2023, the Company issued 50,000 shares of common stock for $ 50,000.

 On December 11, 2023, the Company issued 10,000 shares
of common stock for $ 10,000.

 On December 13, 2023, the Company issued 100,000 shares of common stock for $ 100,000.

 On December 14, 2023, the Company issued 50,000 shares of common stock for $ 50,000.

 On December 20, 2023, the Company issued 53,000 shares of common stock
for $ 53,000.

 On December 26, 2023, the Company issued 50,000 shares of common stock for $ 50,000.

 On January 8, 2024, the Company issued 8,000 shares of common stock for $ 8,000.

 F- 18

 Item
9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 We
have had no disagreements with our accountants required to be disclosed pursuant to Item 304 of Regulation S-K.

 Item
9A. Controls and Procedures

 Evaluation
of Disclosure Controls and Procedures

 The
Company's Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company's disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the year ended September 30, 2023.
Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period,
the Company's disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange
Act.

 Management's
Annual Report on Internal Control over Financial Reporting

 The
management of the Company is responsible for the preparation of the financial statements and related financial information appearing
in this Annual Report on Form 10-K. The financial statements and notes have been prepared in conformity with accounting principles generally
accepted in the United States of America. The management of the Company is also responsible for establishing and maintaining adequate
internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. A company's internal
control over financial reporting is defined as a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Our internal control over financial reporting includes those policies and procedures that:

 Pertain
 to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
 of the Company;

 Provide
 reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
 generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with
 authorizations of management and the board of directors of the Company; and

 Provide
 reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's
 assets that could have a material effect on the financial statements.

 Management,
including the Chief Executive Officer and Chief Financial Officer does not expect that the Company's disclosure controls, and internal
controls will prevent all error and all fraud. Because of its inherent limitations, a system of internal control over financial reporting
can provide only reasonable, not absolute, assurance that the objectives of the control system are met and may not prevent or detect
misstatements. Further, over time, control may become inadequate because of changes in conditions or the degree of compliance with the
policies or procedures may deteriorate.

 With
the participation of the Chief Executive Officer and Chief Financial Officer, our management evaluated the effectiveness of the Company's
internal control over financial reporting as of September 30, 2021, based upon the framework in Internal Control –Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, our management
has concluded that, as of September 30, 2023, the Company had material weaknesses in its internal control over financial reporting and
the Company's internal control over financial reporting was not effective. Specifically, management identified the following material
weaknesses at September 30, 2023:

 1.

 Lack
 of oversight by independent directors in the establishment and monitoring of required internal controls and procedures;

 2.

 Lack
 of functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls
 and procedures;

 3.

 Insufficient
 personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting and
 to allow for proper monitoring controls over accounting;

 4.

 Insufficient
 written policies and procedures over accounting transaction processing and period end financial disclosure and reporting processes.

 To
remediate our internal control weaknesses, management intends to implement the following measures:

 The Company will add sufficient number of independent directors
to the board and appoint an audit committee.

 The Company will add sufficient knowledgeable accounting personnel
to properly segregate duties and to affect a timely, accurate preparation of the financial statements.

 Upon the hiring of additional accounting personnel, the Company
will develop and maintain adequate written accounting policies and procedures.

 The
additional hiring is contingent upon the Company's efforts to obtain additional funding through equity or debt for its continued
operational activities and corporate expenses. Management provides no assurances that it will be able to do so.

 We
understand that remediation of material weaknesses and deficiencies in internal controls are a continuing work in progress due to the
issuance of new standards and promulgations. However, remediation of any known deficiency is among our highest priorities. Our management
will periodically assess the progress and sufficiency of our ongoing initiatives and adjust as and when necessary.

 As
a smaller reporting company, we are not required to provide, and this annual report does not include an attestation report of our registered
public accounting firm regarding internal control over financial reporting.

 Changes
in Internal Control over Financial Reporting

 Except
as set forth above, there were no changes in our internal control over financial reporting that occurred during the period covered by
this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 Limitations
on the Effectiveness of Controls

 The
Company's management, including the CEO and CFO, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of the
control system must reflect that there are resource constraints and that the benefits must be considered relative to their costs. Because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments
in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented
by the individual acts of some persons, by collusion of two or more people, or by management override of controls. The design of any
system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that
any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls
effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration
in the degree of compliance with policies or procedures.

 Item
9B. Other Information.

 None.

 PART
III

 Item
10. Directors, Executive Officers, and Corporate Governance.

 The
following table sets forth information with respect to persons who are serving as directors and officers of the Company. Each director
holds office until the next annual meeting of shareholders or until his successor has been elected and qualified.

 Name

 Age

 Position

 Judith
 S. Miller

 Interim
 Chief Executive Officer, Interim Chief Financial Officer (2)

 Clayton
 Yates

 Chief
 Scientific Officer, Director (1)

 Jesse
 Jaynes

 Chief
 Research Officer, Director (1)

 (1)
 on January 12, 2021.

 (2)
 on June 20, 2023.

 Biographies
of Directors and Officers

 The
following is a brief account of the education and business experience during at least the past five years of each director, executive
officer, and key employee of our company, indicating the person's principal occupation during that period, and the name and principal
business of the organization in which such occupation and employment were carried out.

 Judith
S. Miller, Esq.

 Judith
("Judy") S. Miller is a member of the Florida Bar, currently living in Chapel Hill, North Carolina. Judy was a seed-investor
in the precursor company that was acquired by the Company in the reverse merger in 2022 (and which is now the Company's wholly
owned subsidiary: Genvor Inc., a Delaware corporation). She was a paid Consultant with the Company for 18 months prior to the combination
of Genvor Inc. and the Company. She has continued to acquire more shares and owns approximately 6% of the Company and is familiar with
the operations of the Company to date. Her focus is on completing the process for the Company to have its common stock quoted for trading
on the OTC Link alternative trading system operated by OTC Markets Group Inc., securing R&D funding for further enhancing the value
for the Company's peptide technology, and conducting the search for a biotech-oriented, experienced manager as the next CEO of
the Company. Judy has served as a Business Strategist for both domestic and international entities, is a Real Estate Developer and Film
& Theater Producer. Judy earned her BAED and JD from the University of Florida, where she was also an Instructor of Business Law.

 Dr.
Clayton Yates, Ph. D.

 Dr.
Clayton Yates, Ph. D., co-founded Genvor and is Chairman of the Board of Genvor. His research is currently funded by the National
Cancer Institute (NCI) and Department of Defense (DOD) Congressionally Medical Directed Research Programs. Dr. Yates is also a
scientist at Tuskegee University, focused on identifying molecular targets for therapeutic intervention in prostate, breast, and
pancreatic cancers. Dr. Yates received his initial training at the University of Pittsburgh School of Medicine in the Department of
Cellular and Molecular Pathology. He completed additional training in Tissue Engineering and Regenerative Medicine jointly from the
McGowan Institute for Regenerative Medicine and Massachusetts Institute of Technology (MIT). Dr. Yates completed his post-doctoral
training at Emory University School of Medicine in the Department of Molecular Urology.

 Dr.
Jesse Jaynes, Ph. D.

 Dr.
Jesse Jaynes, Ph. D., co-founded Genvor as well, and he leads the research for Genvor and manages ongoing, critical communication with
our outside research and development partners and associations. Dr. Jaynes is one of the world's leading authorities on therapeutic
peptide design and has vast experience in drug development for various applications, including agriculture, animal health, wound healing,
and oncology. Dr. Jaynes' research is funded by USDA, NSF, and NIH. He has more than 60 United States and foreign patents and has
authored over 100 scientific journal articles. Over the past 15 years, Dr. Jaynes has served on the board of numerous life science companies
and is currently the Chief Technology Officer for the National Cancer Coalition. Dr. Jaynes is a Professor of Biochemistry at Tuskegee
University. Dr. Jaynes completed his doctoral training at Brigham Young University, Utah.

 There
are no family relationships among any of our directors and executive officers.

 Our
directors are elected at the annual meeting of the shareholders, with vacancies filled by the Board of Directors, and serve until their
successors are elected and qualified, or their earlier resignation or removal. Officers are appointed by the board of directors and serve
at the discretion of the board of directors or until their earlier resignation or removal. Any action required can be taken at any annual
or special meeting of stockholders of the corporation which may be taken without a meeting, without prior notice and without a vote,
if consent of consents in writing setting forth the action so taken, shall be signed by the holders of the outstanding stock having not
less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled
to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office, its principle
place of business, or an officer or agent of the corporation having custody of the book in which the proceedings of meetings are recorded.

 As
we have recently devoted efforts to exploring the intersection of technology and wholistic technology-based health treatments for a variety
of mental health conditions, from autism to dementia and Alzheimer's, we have also retained Board of Advisors composed of advisors
we believe are competent to advise us regarding technology, sports health issues and treatments, and PTSD.

 Indemnification
of Directors and Officers

 Section
78.138 of the Nevada Revised Statutes ("NRS") provides that a director or officer will not be individually liable unless
it is proven that (i) the director's or officer's acts or omissions constituted a breach of his or her fiduciary duties,
and (ii) such breach involved intentional misconduct, fraud or a knowing violation of the law. Section 78.7502 of NRS permits a company
to indemnify its directors and officers against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred
in connection with a threatened, pending or completed action, suit or proceeding if the officer or director (i) is not liable pursuant
to NRS 78.138 or (ii) acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to the
best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer
or director was unlawful. Section 78.751 of NRS permits a Nevada company to indemnify its officers and directors against expenses incurred
by them in defending a civil or criminal action, suit or proceeding as they are incurred and in advance of final disposition thereof,
upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court
of competent jurisdiction that such officer or director is not entitled to be indemnified by the company. Section 78.751 of NRS further
permits the company to grant its directors and officers additional rights of indemnification under its articles of incorporation or bylaws
or otherwise. Section 78.752 of NRS provides that a Nevada company may purchase and maintain insurance or make other financial arrangements
on behalf of any person who is or was a director, officer, employee or agent of the company, or is or was serving at the request of the
company as a director, officer, employee or agent of another company, partnership, joint venture, trust or other enterprise, for any
liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee or agent,
or arising out of his status as such, whether or not the company has the authority to indemnify him against such liability and expenses.

 Our
Articles of Incorporation provide that no director or officer of the Company will be personally liable to the Company or any of its stockholders
for damages for breach of fiduciary duty as a director or officer; provided, however, that the foregoing provision shall not eliminate
or limit the liability of a director or officer (i) for acts or omissions which involve intentional misconduct, fraud or knowing violation
of law, or (ii) the payment of dividends in violation of Section 78.300 of NRS. In addition, our Bylaws implement the indemnification
and insurance provisions permitted by Chapter 78 of the NRS by providing that the Company shall indemnify its directors to the fullest
extent permitted by the NRS and may, if and to the extent authorized by the board of directors, so indemnify its officers and any other
person whom it has the power to indemnify against liability, reasonable expense or other matter whatsoever; and the Company may at the
discretion of the board of directors purchase and maintain insurance on behalf of any person who holds or who has held any position identified
in the paragraph above against any and all liability incurred by such person in any such position or arising out of his status as such.

 Insofar
as indemnification by us for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling
the company pursuant to provisions of our articles of incorporation and bylaws, or otherwise, we have been advised that in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event
that a claim for indemnification by such director, officer or controlling person of us in the successful defense of any action, suit
or proceeding is asserted by such director, officer or controlling person in connection with the securities being offered, we will, unless
in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.

 Director
Compensation

the year ended September 30, 2023, and 2022, we did not have an independent director. Directors that
were employees were not paid any fees for their role as director.

 Involvement
on Certain Material Legal Proceedings During the Last Five Years

 No
director, officer, significant employee, or consultant has been convicted in a criminal proceeding, exclusive of traffic violations.

 No
bankruptcy petitions have been filed by or against any business or property of any director, officer, significant employee, or consultant
of the Company nor has any bankruptcy petition been filed against a partnership or business association where these persons were general
partners or executive officers.

 No
director, officer, significant employee, or consultant has been permanently or temporarily enjoined, barred, suspended, or otherwise limited
from involvement in any type of business, securities, or banking activities.

 No
director, officer or significant employee has been convicted of violating a federal or state securities or commodities law.

 Directors'
and Officers' Liability Insurance

 The
Company does not have directors' and officers' liability insurance insuring our directors and officers against liability
for acts or omissions in their capacities as directors or officers.

 Code
of Ethics

 We
intend to adopt a code of ethics that applies to our officers, directors, and employees, including our principal executive officer and
principal accounting officer, but have not done so to date due to our relatively small size. We intend to adopt a written code of ethics
in the near future.

 Corporate
Governance and Board Independence

 Our
Board of Directors consists of two directors and has not established a Nominating or Governance Committees as standing committees.
The Board does not have an executive committee or any committees performing a similar function. We are not currently listed on a national
securities exchange or in an inter-dealer quotation system that has requirements that a majority of the board of directors be independent.

 Due
to our lack of operations and size, and since we are not currently listed on a national securities exchange, we are not subject to any
listing requirements mandating the establishment of any particular committees; all functions of a nominating/governance committee were
performed by our whole board of directors. Our board of directors intends to appoint such persons and form such committees as are required
to meet the corporate governance requirements imposed by the national securities exchanges as necessary. Our board of directors does
not believe that it is necessary to have such committees at the early stage of the company's development, and our board of directors
believes that the functions of such committees can be adequately performed by the members of our board of directors.

 We
believe that our board of directors is capable of analyzing and evaluating our financial statements and understanding internal controls
and procedures for financial reporting. We believe that retaining an independent director who would qualify as an "audit committee
financial expert" would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our
development and the fact that we have not generated any material revenues to date.

 Board
Leadership Structure and the Board's Role in Risk Oversight.

 The
Board of Directors is led by a chairman. The Board believes its current leadership structure best serves the objectives of the
Board's oversight of management, the Board's ability to carry out its roles and responsibilities on behalf of the
Company's shareholders, and the Company's overall governance. The Board periodically reviews the leadership structure to
determine whether it continues to best serve the Company and its shareholders.

 Audit Committee and Financial Expert; Committees

 The Company does not have an audit committee. We are
not a "listed company" under SEC rules and are therefore not required to have an audit committee comprised of independent
directors.

 The Company has no nominating or compensation committees
at this time. The entire Board participates in the nomination and audit oversight processes and considers executive and director compensation.
Given the size of the Company and its stage of development, the entire Board is involved in such decision-making processes. Thus, there
is a potential conflict of interest in that our directors and officers have the authority to determine issues concerning management compensation,
nominations, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our
executive officers or directors.

 Compliance with Section 16(A) of the Exchange Act

 Section 16(a) of the Exchange Act requires the Company's
directors, executive officers and persons who beneficially own 10% or more of a class of securities registered under Section 12 of the
Exchange Act to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Directors, executive officers and
greater than 10% stockholders are required by the rules and regulations of the SEC to furnish the Company with copies of all reports filed
by them in compliance with Section 16(a).

 Based solely on our review of certain reports filed
with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, the reports
required to be filed with respect to transactions in our common stock during the fiscal year ended December 31, 2023, were timely.

 Family relationships

 There are no family relationships among any of our officers or directors.

 Item
11. Executive Compensation

 The
table below sets forth, for the year ended September 30, 2023 ("2023") and 2022 ("2022"),
the compensation earned by our executive officers and former executive officers.

 Deferred

 Option and

 All Other

 Name and

 Compen-

 Stock

 Warrant

 Compen-

 Principal Position

 Salary

 sation

 Bonus

 Awards

 Awards

 sation

 Total

 Judith S. Miller, Esq.

 2023

 $
 65,000

 $
 -

 $
 -

 $
 -

 $
 600,000
 (2)

 $
 -

 $
 665,000

 Interim Chief Executive Officer and Chief Financial Officer (1)

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Dr. Clayton Yates

 2023

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Chief Scientific Officer, Director (3)

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Dr. Jesse Jaynes

 2023

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Chief Research Officer, Director (3)

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Bradley White

 2023

 $
 80,625

 $
 -

 $
 -

 $
 -

 $
 -

 $
 66,348
 (5)

 $
 146,973

 Former Chief Executive Officer, Chief Financial Officer, and Director (4)

 2022

 $
 125,986

 $
 -

 $
 -

 $
 -

 $
 -

 $
 265,945
 (5)

 $
 391,931

 Robert Bubeck

 2023

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Former Chief Executive Office, Chief Financial Officer and Director (6)

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Margaret McLaughlin

 2023

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 Former Secretary and Director (6)

 2022

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 $
 -

 (1)

on June 20, 2023.

 (2)

 Issued 600,000 warrants for milestones in consulting agreement. The warrants
were issued on September 29, 2023, and expire on March 29, 2025, with an exercise price of $0.001.

 (3)

 (4)

 (5)

on January 12, 2021.

on January 12, 2021, and terminated on June 20, 2023.

 Consists
 of Company payments for Mr. White's personal expenses.

 (6)

 Resigned on January 12, 2021.

 The Company has not entered into employment or similar
agreements with any of our executive officers or directors except as follows:

 On October 5, 2023, the
Company entered into an Interim CEO & Executive Consultant Agreement (the "Executive Consulting Agreement")
with Judith S. Miller, pursuant to which Judith S. Miller would serve as the Company's Interim CEO, and with the Executive Consulting
Agreement intended to be considered effective as of June 20, 2023, the date of Ms. Miller's original appointment as Interim CEO
of the Company. Under the Executive Consulting Agreement, which can be terminated at any time with or without cause by the Company and
upon 30 days' advance written notice by Ms. Miller, Ms. Miller will act as the Interim CEO of the Company and, among other management
duties, assist the Company in recruiting a full-time CEO and/or agricultural biotechnology management professional. Following the appointment
of a full-time CEO, Ms. Miller will be retained as an executive consultant for a period of 6 months thereafter.

 While Ms. Miller is Interim
CEO, she will be compensated as follows:

 (i)

 Ms. Miller will be paid a cash fee of $20,000 per month, which will be accrued by the Company if funds are not available.

 (ii)

 Ms. Miller will receive warrants to purchase shares of Company common stock at a $0.001 per share exercise price, exercisable on a cashless basis, with a 12-month term after issuance ("Warrants") for 350,000 shares of Company common stock upon execution of the Executive Consulting Agreement.

 (iii)

 Ms. Miller will receive Warrants for 250,000 shares of Company common stock upon clearance by the OTCQB marketplace and FINRA for an identified market maker to begin trading the Company's common stock, and the issuance of a ticker symbol for the Company's common stock.

 (iv)

 Ms. Miller will receive Warrants for 250,000 shares of Company common stock upon the Company's obtaining the results of scientific studies conducted a Confidential target for further use by the Company.

 (v)

 Ms. Miller will receive Warrants for 250,000 shares of Company common stock upon the Company's receipt of a working agreement with this Confidential target a licensing and royalty arrangement with them.

 (vi)

 Ms. Miller will receive Warrants for 250,000 shares of Company common stock upon the Company resolving all claims against Bradley White, either through litigation or settlement.

 (vii)

 Ms. Miller will receive Warrants for 100,000 shares of Company common stock upon the Company hiring a full-time CEO.

 (viii)

 Ms. Miller will receive Warrants for 250,000 shares of Company common stock upon the Company (i) planning and launching a secondary investment offering, expected to be from $20,000,000 to $30,000,000, with the first tranche or raise objective expected to be from $4,000,000 to $7,000,000, and (ii) the Company's successful minimum raise of $3,000,000 in that offering.

 Notwithstanding the foregoing,
Warrants will not be issued to Ms. Miller until the date that the Company's common stock has an average daily trading volume of
at least 1,000 shares for at least 5 consecutive days as reported by OTCMarkets.com. During the 6 months following the date that a full-time
CEO is appointed, and Ms. Miller will be an executive consultant, and Ms. Miller will be paid a cash fee of $10,000 per month and an equity
fee consisting of Warrants for 25,000 shares of Company common stock per month.

 Outstanding Equity Awards at Fiscal Year-End

 No executive officer named above had any unexercised
options or stock that had not vested, or equity incentive plan awards outstanding as of September 30, 2023, and 2022. As described above,
Ms. Miller has now received 600,000 Warrants considered effective as of September 30, 2023, and such Warrants are considered vested.

 Director Compensation

 No member of our board of directors received any compensation
for his or her services as a director during the fiscal years ending September 30, 2023, and 2022, nor do they currently receive any compensation
for such services.

 Equity Incentive Plans

 Long-Term Incentive Plans. The Company
does not provide its officers or employees with pension, stock appreciation rights, long-term incentive or other plans, nor does it provide
non-qualified deferred compensation to its officers or employees, and therefore, the Summary Compensation Table above does not include
columns for nonequity incentive plan compensation and nonqualified deferred compensation earnings since there were none.

 Employee
Pension, Profit Sharing or other Retirement Plans. The Company does
not have a defined benefit, pension plan, profit sharing or other retirement plan, although it may adopt one or more of such plans in
the future.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The
following table sets forth certain information regarding beneficial ownership of our common stock as of January 15, 2023, by (i) each person
known by us to be the beneficial owner of more than 5% of any class of our voting equity, (ii) each director and each of our named executive
officers and (iii) all executive officers and directors as a group.

 The
number of shares of stock beneficially owned by each person is determined under the rules of the SEC and the information is not necessarily
indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which such
person has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60
days after the date hereof, through the exercise of any stock option, warrant or other right. Unless otherwise indicated, each person
has sole investment and voting power (or shares such power with his or her spouse) with respect to the shares set forth in the following
table. The inclusion herein of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those
shares.

 The
information reflected in the following table was, unless otherwise specified, the address of each of the persons set forth below or
is in care of the Company at the Company's address.

 Title of Class

 Name & Address of
 Beneficial Owners

 Amount & Nature of Beneficial Ownership (1)

 Percent of Class (2)

 Judith S. Miller (3)

 1,106,170
 (4)

 5.8
 %

 Dr. Clayton Yates (5)

 7,312,623
 (6)

 27.6
 %

 Dr. Jesse Jaynes (7)

 6,767,623
 (8)

 26.0
 %

 All Officers and Directors as a Group

 15,186,416

 44.1
 %

 John Coutris

 1,789,843
 (9)

 8.5
 %

 Series B Preferred Stock

 Dr. Clayton Yates

 731,262

 46.9
 %

 Series B Preferred Stock

 Dr. Jesse Jaynes

 676,762

 43.4
 %

 Series B Preferred Stock

 All Officers and Directors as a Group

 1,408,024

 90.4
 %

 Series B Preferred Stock

 John Coutris

 9.6
 %

 Series A Preferred Stock

 Dr. Clayton Yates

 %

 Series A Preferred Stock

 Dr. Jesse Jaynes

 %

 Series A Preferred Stock

 All Officers and Directors as a Group

 %

 (1)

 Beneficial
 ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment
 power with respect to securities. Each of the beneficial owners listed above has direct ownership of and sole voting power and investment
 power with respect to the shares of the Company's common stock unless otherwise stated herein.

 (2)

 As
of November 7, 2023, a total of 19,216,936 shares of the Company's common stock, 6 shares of Series A Preferred Stock, and 1,558,024
shares of Series B Preferred Stock are considered to be outstanding pursuant to SEC Rule 13d-3(d)(1). For each beneficial owner above,
any shares of common stock issuable upon conversion of Series A Preferred Stock or Series B Preferred Stock within 60 days have been
included for purposes of calculating the relevant percentage ownership. Each share of Series A Preferred Stock converts into 1 share
of common stock (but has super-voting power and entitles the holder to 10,000,000 votes), and each share of Series B Preferred Stock
converts into 10 shares of common stock at the election of the holder (and entitles the holder to 10 votes).

 (3)

 Interim
 Chief Executive Officer and Chief Financial Officer.

 (4)

 1,106,170 shares of common stock are held in the name of Good Works Funding
Inc., which may be deemed to be beneficially owned by Ms. Miller.

 (5)

 Chief
 Scientific Officer & Director.

 (6)

 731,262
 shares of Series B Preferred Stock are held in the name of ACT Holdings LLC, which may be deemed to be beneficially owned by Dr.
 Yates, and such shares of Series B Preferred Stock are convertible into 7,312,620 shares of common stock. 3 shares of Series A Preferred Stock are held directly by Dr. Yates, and such shares of Series A Preferred Stock
are convertible into 3 shares of common stock.

 (7)

 Chief
 Research Officer & Director.

 (8)

 476,762
 shares of Series B Preferred Stock are held jointly in the name of Dr. Jaynes and his spouse, 200,000 shares of Series B Preferred
 Stock held in the name of the Jaynes Investment LLC, which may be deemed to be beneficially owned by Dr. Jaynes, and such shares
 of Series B Preferred Stock are convertible into 6,767,620 shares of common stock. 3 shares of Series A Preferred Stock are held directly by Dr. Jaynes, and such shares of Series A Preferred Stock
are convertible into 3 shares of common stock.

 (9)

 198,637 shares of common stock are held in the name of John Coutris, 91,206
shares of common stock are held in the name of Callie Coutris, John Coutris's spouse, and 150,000
 shares of Series B Preferred Stock are held in the name of PJ Advisory Group, which may be deemed to be beneficially owned by
 Mr. Coutris. Such shares of preferred stock are convertible into 1,500,000 shares of common stock. The address of
 John Coutris, Callie Coutris, and PJ Advisory Group is 7227 Centenery Ave., Dallas, Texas, 75225.

 Item
13. Certain Relationships and Related Transactions

 Transactions
with Related Persons

 None

 The
Company does not own or rent property. The office space is provided by an officer at no charge.

 Director
Independence

 We
currently do not have any independent directors, as the term "independent" is defined in Section 803A of the NYSE American
Company Guide. The Board has made its determination as to director independence based on the definition of "independence"
as defined under the rules of the New York Stock Exchange ("NYSE") and NYSE American.

 Item
14. Principal Accounting Fees and Services.

 The
following table sets forth the fees billed by our principal independent accountants for the year ended September 30, 2023, and the nine
months ended September 30, 2022, for the categories of services indicated.

 Nine Months

 Year Ended

 Ended

 2023

 2022

 Audit fees

 $
 72,900

 $
 42,000

 Audit related fees

 -

 -

 Tax fees

 -

 -

 All other fees

 -

 -

 Total

 $
 72,900

 $
 42,000

 On
December 16, 2020, we engaged Turner, Stone & Company, L.L.P. ("Turner") of Dallas, Texas, as our new independent registered
public accounting firm.

 Audit
fees. Consists of fees billed for the audit of our annual financial statements and review of our interim financial information and
services that are normally provided by the accountant in connection with year-end and quarter-end statutory and regulatory filings or
engagements.

 Audit-related
fees. Consists of fees billed for services relating to review of other regulatory filings including registration statements, periodic
reports and audit related consulting.

 Tax
fees. Consists of professional services rendered by our principal accountant for tax compliance, tax advice and tax planning.

 Other
fees. Other services provided by our accountants.

 Item
15. Exhibits, Financial Statement Schedules

 Exhibit

 Description

 3.1

 Florida Articles of Incorporation (incorporated by reference to Exhibit 3.A to our Registration Statement on Form S-1, filed on May 4, 2020)

 3.2

 Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.2 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)

 3.3

 Certificate of Correction to Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)

 3.4

 Certificate of Amendment to Articles of Incorporation, filed June 24, 2022 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on July 1, 2022)

 3.5

 Bylaws (incorporated by reference to Exhibit 3.B to our Registration Statement on Form S-1, filed on May 4, 2020)

 10.1*

 Exchange Agreement, by and between the Company and Genvor Inc. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2021)

 10.2*

 Agreement and Plan of Merger, by and between the Company, Genvor Inc., and Genvor Acquisition Corp. (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 21, 2022)

 10.3

 Interim CEO & Executive Consultant Agreement, by and between Genvor Incorporated and Judith S. Miller, dated June 20, 2023 (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on October 10, 2023)

 31.1**

 Certification of CEO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 31.2**

 Certification of CFO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 32.1**

 Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 32.2**

 Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 101.INS***

 101.SCH***

 101.CAL***

 101.DEF***

 101.LAB***

 101.PRE***

 Cover

 *
Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit
will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request
confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

 **
Filed herewith.

 ***
for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 /s/
 Judith S. Miller

 January
 16, 2024

 Chief
 Executive Officer and

 Date

 Chief
 Financial Officer

 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

 /s/
 Clayton Yates

 January
 16, 2024

 Director

 Date

 /s/
 Jesse Jaynes

 January
 16, 2024

 Director

 Date